APOL1 inhibitors and methods of use

Abstract

Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1 -mediated disease, disorder, or condition in an individual.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application Serial No. 63 / 300,592, filed January 18, 2022, U.S. Provisional Application Serial No. 63 / 311,668, filed February 18, 2022, U.S. Provisional Application Serial No. 63 / 332,553, filed April 19, 2022, U.S. Provisional Application Serial No. 63 / 400,359, filed August 23, 2022, and U.S. Provisional Application Serial No. 63 / 422,341, filed November 3, 2022, each of which is hereby incorporated herein by reference in its entirety. BACKGROUND OF THE INVENTION

[0002] Apolipoprotein LI (APOL1) is a pore forming innate immunity factor, protecting individuals from trypanosome parasites (Vanhamme, L. et al. Nature (2003) 422, 83-87). The secreted form of APOL1 circulates in blood as part of distinct high-density lipoprotein (HDL) complexes, known as trypanosome lytic factors (TLFs) (Rifkin, M. R. Proc. Natl. Acad. Sci. USA. (1978) 75, 3450-3454; Raper, J. et al. Infect. Immun. (1999) 67, 1910-1916). TLFs are internalized by the parasites through endocytosis (Hager, K. M. et al. J. Cell Biol. (1994) 126, 155-167). Within trypanosomes, APOL1 forms cation pores, causing ion flux, swelling, and eventual lysis (Rifkin, M. R. Exp. Parasitol. (1984) 58, 81-93; Molina-Portela, M. P. et al. Mol. Biochem. Parasitol. (2005) 144, 218-226; Perez-Morga, D. et al. Science. (2005) 309, 469-472; Thomson, R. & Finkelstein, A. Proc. Natl. Acad. Sci. USA. (2015) 112, 2894-2899).

[0003] Several Trypanosoma brucei subspecies (T.b. rhodesiense and T. b. gambiense) developed resistance mechanisms to APOL1-dependent killing (Pays, E. et al. Nat. Rev. Microbiol. (2014) 12, 575-584). Positive selection resulted in APOL1 variants, G1 (S342G, I384M) and G2 (N388A, Y389A), capable of interfering with these resistance mechanisms (Genovese, G. et al. Science. (2010) 329, 841-845). However, individuals with any binary combination of these variants (Gl / Gl, G2 / G2, or G1 / G2), have a greater risk of developing a variety of chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN) (Genovese, G. et al. Science. (2010) 329, 841-845; Tzur, S. et al. Hum. Genet. (2010) 128, 345-350; Kopp, J. B. et al. J. Am. Soc. Nephrol. (2011) 22, 2129-2137), sickle cell nephropathy (Ashley-Koch, A. E. et al. Br. J. Haematol. (2011) 155, 386-394), lupus nephritis (Freedman, B. I. et al. Arthritis Rheumatol. (2014) 66, 390-396), and an increased rate of Glomerular Filtration Rate (GFR) decline in diabetic kidney disease (Parsa, A. et al. N. Engl. J. Med. (2013) 369, 2183-2196). The APOL1 high-risk genotype has also been associated with COVID-19 associated nephropathy and other viral nephropathies (Shetty, A. et al. J. Am. Soc. Nephrol. (2021) 32, 33-40; Chang, J. H. et al. Am. J. Kidney Dis. (2019) 73, 134-139). Moreover, decreased renal allograft survival has been observed after deceased-donor kidney transplantations from APOL1 high-risk genotype donors (Freedman, B. I. et al. Transplantation. (2016) 100, 194-202). In addition, having two APOL1 risk alleles increases risk for preeclampsia (Reidy, K. J. et al. Am. J. Hum. Genet. (2018) 103, 367-376) and sepsis (Chaudhary, N. S. et al. Clin. J. Am. Soc. Nephrol. (2019) 14, 1733-1740). There are no approved therapies for APOL1-associated nephropathy, and patients are treated based on the standard of care for their underlying form of chronic kidney disease. This presents a clear unmet need for therapies targeted to people with the APOL1 high-risk genotype.

[0004] Numerous studies have shown that APOL1 risk variants are toxic when overexpressed in human cells (Wan, G. et al. J. Biol. Chern. (2008) 283, 21540-21549; Lan, X. et al. Am. J. Physiol. Renal Physiol. (2014) 307, F326-F336; Olabisi, O. A. et al. Proc. Natl. Acad. Sci. USA. (2016) 113, 830-837; Ma, L. et al. J. Am. Soc. Nephrol. (2017) 28, 1093-1105; Lannon, H. et al. Kidney Int. (2019) 96, 1303-1307). Recent findings suggest that this toxicity is associated with APOL1 pore function (Giovinazzo, J. A. et al. eLife. (2020) 9, e51185). Thus, there is a need to develop compounds suitable for inhibiting APOL1 activity and methods for inhibiting the activity of APOL1 using such compounds. BRIEF SUMMARY OF THE INVENTION

[0005] This disclosure describes compounds and compositions that may be useful for the treatment of APOL1-mediated diseases, including a variety of chronic kidney diseases such as FSGS, hypertension-attributed kidney disease, HIV AN, sickle cell nephropathy, lupus nephritis, diabetic kidney disease, viral nephropathy, COVID-19 associated nephropathy, and APOL1-associated nephropathy. The compounds and compositions may treat other APOL1-mediated disorders such as preeclampsia and sepsis. Additionally, for individuals with the APOL1 high-risk genotype, the disclosed compounds and may prevent the onset of non-diabetic renal disease and / or delaying the progression of any form of chronic kidney disease. The disclosed chemical matter may also prevent and / or delay progressive renal allograft loss in patients who have received a kidney transplant from a high-risk APOL1 genotype donor.

[0006] In one aspect, provided is a compound of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-ealkoxy, and Ci-ealkyl, wherein the Ci-ealkoxy of R1 is optionally substituted with one or more halo, and the Ci-ealkyl of R1 is optionally substituted with one or more halo; R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more deuterium, halo, -OH, -NH2, or Ci-ealkoxy, and the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH; R3, if present, is Ci-ealkyl; L1 is Ci-ealkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more deuterium or Ci-ealkyl, and wherein the Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy; L2 is O or N(RX), wherein Rx is H or Ci-ealkyl; and either (1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl, the Ci-ealkylene of L3 is optionally substituted with one or more -OH or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, and the 3-10 membered heterocyclyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl; X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra; (ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl; (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, (iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-6 alkyl, or 3-10 membered heterocycle, wherein the 3-10 membered heterocycle of Re is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH , oxo or -S(O)2Ra , (vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl), (viii) -CN, (ix) -(CH2)?OH, wherein q is an integer from 0-6, (x) -C(O)-Ci-ealkyl, or (xi) -P(O)(Ci-6alkyl)2; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-6alkyl, -C(O)-Ci-6alkyl, -C(0)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, and wherein the C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH and the C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, C3-iocycloalkyl, or Ci-ealkyl, and wherein the Ci-ealkyl of the C3-iocycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium, or halo, and the 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and the 3-10 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and wherein the Ci-ealkyl of the 3-10 membered heterocyclyl of Rc is further optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-ealkyl, (ii) C3-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, (iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, or (iv) NH(Ci-ealkyl); R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo or -OH, and the Ci-ealkoxy of R5 is optionally substituted with one or more halo; X3 is N or C(R6); X4 is N or C(R7); and R6 and R7 are each independently H or halo.

[0007] In one aspect, provided is a compound of formula (I’): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-ealkoxy, or Ci-ealkyl, wherein the Ci-ealkoxy of R1 is optionally substituted with one or more halo, and the Ci-ealkyl of R1 is optionally substituted with one or more halo; R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more halo, -OH, -NH2, or Ci-ealkoxy, and the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH; R3, if present, is Ci-ealkyl; L1 is Ci-ealkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more Ci-ealkyl, and wherein the Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy; L2 is O or N(RX), wherein Rx is H or Ci-ealkyl; and either (1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl is optionally substituted with one or more -OH or Ci-ealkyl, the Ci-ealkylene of L3 is optionally substituted with one or more -OH or Ci-ealkyl, and the 3-10 membered heterocyclyl is optionally substituted with one or more -OH; X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra; (ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl; (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, C1-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, (iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, C1-6 alkyl, or 3-10 membered heterocycle, wherein the 3-10 membered heterocycle is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH , oxo, or -S(O)2Ra , (vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl), (viii) -CN, (ix) -(CH2)?OH, wherein q is an integer from 0-6, (x) -C(O)-Ci-ealkyl, or (xi) -P(O)(Ci-6alkyl)2; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4 and the atoms to which they are attached to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of halo, oxo, Ci-6alkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, and wherein the C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH and the C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, C3-iocycloalkyl, or Ci-ealkyl, and wherein the Ci-ealkyl of the C3-iocycloalkyl of Rb is further optionally substituted with one or more -OH, and the 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and the 3-10 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and wherein the Ci-ealkyl of the 3-10 membered heterocyclyl of Rc is further optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl, (ii) Cs-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, or (iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl; R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy of R5 is optionally substituted with one or more halo; and R6 and R7 are each independently H or halo.

[0008] In one aspect, provided is a compound of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; R1 if present is, independently at each occurrence, selected from the group consisting of halo, -CN, Ci-ealkoxy or -Ci-ealkyl, wherein the Ci-ealkoxy of R1 is optionally substituted with one or more halo, and the Ci-ealkyl of R1 is optionally substituted with one or more halo; R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more halo, -OH, -NH2, or Ci-ealkoxy, and the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH; R3, if present, is Ci-ealkyl; L1 is Ci-ealkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more Ci-ealkyl, and wherein the Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy; L2 is O or N(RX), wherein Rx is H or Ci-ealkyl; and either (1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more Ci-ealkyl, and the 3-10 membered heterocyclyl is optionally substituted with one or more -OH; X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra, (ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl, (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, C1-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, (iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, C1-6 alkyl, or 3-10 membered heterocycle, wherein the 3-10 membered heterocycle is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl or oxo, (vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl), or (viii) -CN; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of halo, oxo, Ci-6alkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, or -S(O)2-Ci-ealkyl, and the C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, and the 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, and the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl, or (ii) C3-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(0)-N(Ci-6alkyl)2,-C(0)-C3-ioheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, or (iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl; R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo or -OH, and wherein the Ci-ealkoxy is optionally substituted with one or more halo; and R6 and R7 are each independently H or halo.

[0009] Any embodiments provided herein of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, are also embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0010] Any embodiments provided herein of a compound of formula (I) or (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, are also embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0011] In one aspect, provided herein is a compound of formula (I-A): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: n is 1 or 2; and wherein m,p, R1, R2, R3, L1, L3, R4, X1, X2, R6, and R7 are as defined elsewhere herein. In another variation, m,p, R1, R2, R3, L1, L3, R4, X1, X2, R6, and R7 of formula (I-A) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0012] In one aspect, provided herein is a compound of formula (I-B): R2 (R^^X / ^0 (R3) / W R? R R^^S r / (I-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m,p, R1, R2, R3, L1, L3, R4, R5, R6, and R7 are as defined elsewhere herein. In another variation, m,p, R1, R2, R3, L1, L3, R4, R5, R6, and R7 of formula (I-B) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0013] In one aspect, provided herein is a compound of formula (I-C): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m,p, R1, R2, R3, L1, L3, R4, and R5 are as defined elsewhere herein. In another variation, m, p, R1, R2, R3, L1, L3, R4, and R5 of formula (I-C) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0014] In one aspect, provided herein is a compound of formula (I-D): R2 (R1)™— (rVCi / \’~o L3 R (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m,pt R1, R2, R3, L1, L3, and R4 are as defined elsewhere herein. In another variation, R1, R2, R3, L1, L3, and R4 of formula (I-D) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0015] In one aspect, provided herein is a compound of formula (I-E): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m,p, R1, R2, R3, L1, X2, R6, R7, and ring A are as defined elsewhere herein. In another variation, m,p, R1, R2, R3, L1, X2, R6, R7, and ring A of formula (I-E) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0016] In one aspect, provided herein is a compound of formula (I-F): R2 r / (R3)^N^ V'~o (I-F), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m,p, R1, R2, R3, L1, R5, and ring A are as defined elsewhere herein. In another variation, m,p, R1, R2, R3, L1, R5, and ring A of formula (I-F) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0017] In one aspect, provided herein is a compound of formula (I-G): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m,p, R1, R2, R3, L1, and ring A are as defined elsewhere herein. In another variation, m, p, R1, R2, R3, L1, and ring A of formula (I-G) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0018] In one aspect, provided herein is a compound of formula (II-A): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m,p, R1, R2, R3, L1, X2, X3, X4, and ring A are as defined elsewhere herein.

[0019] In one aspect, provided herein is a pharmaceutical composition, comprising (i) a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a pharmaceutical composition, comprising (i) a compound of formula (I’), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a pharmaceutical composition, comprising (i) a compound of formula (II), or any embodiment or variation thereof, such as a compound of formula (I), (I’), (I-A) (I-B), (I-C), (ID), (I-E), (I-F), (I-G), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0020] In one aspect, provided herein is a method of modulating APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (IB), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or 16 more pharmaceutically acceptable excipients. In another variation, provided herein is a method of modulating APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (I’), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (I’), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of modulating APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (II), or any embodiment or variation thereof, such as a compound of formula (I), (F), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (II), or any embodiment or variation thereof, such as a compound of formula (I), (II), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0021] In one aspect, provided herein is a method of inhibiting APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (ID), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (IB), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of inhibiting APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (F), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of inhibiting APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (II), or any embodiment or variation thereof, such as a compound of formula (I), (I’), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (II), or any embodiment or variation thereof, such as a compound of formula (I), (F), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0022] In one aspect, provided herein is a method of treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another vatiation, provided herein is a method of treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula (F), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (F), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another vatiation, provided herein is a method of treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula (II), or any embodiment or variation thereof, such as a compound of formula (I), (F), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (II), or any embodiment or variation thereof, such as a compound of formula (I), (I’), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0023] In one aspect, provided herein is a kit, comprising (i) a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (ID), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof. In another variation, provided herein is a kit, comprising (i) a compound of formula (F), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof. In another variation, provided herein is a kit, comprising (i) a compound of formula (II), or any embodiment or variation thereof, such as a compound of (I), (I’), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof.

[0024] In some aspect, provided herein are methods of preparing a compound of formula (I), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (ID), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In another variation, provided herein are methods of preparing a compound of formula (F), or any embodiment or variation thereof, such as a compound of formula (I), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), or (I-G), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In another variation, provided herein are methods of preparing a compound of formula (I’), or any embodiment or variation thereof, such as a compound of formula of (I), (F), (I-A) (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), or (II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. DETAILED DESCRIPTION OF THE INVENTION

[0025] Unless clearly indicated otherwise, the terms “a,” “an,” and the like, refer to one or more.

[0026] As used herein, “about” a parameter or value includes and describes that parameter or value per se. For example, “about X” includes and describes X per se.

[0027] “Individual” refers to mammals and includes humans and non-human mammals. Examples of individuals include, but are not limited to, some primates and humans. In some embodiments, individual refers to a human.

[0028] As used herein, an “at risk” individual is an individual who is at risk of developing a disease or condition. An individual “at risk” may or may not have a detectable disease or condition, and may or may not have displayed detectable disease prior to the treatment methods described herein. “At risk” denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art. An individual having one or more of these risk factors has a higher probability of developing the disease or condition than an individual without these risk factor(s).

[0029] “Treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired results may include one or more of the following: decreasing one or more symptom resulting from the disease or condition; diminishing the extent of the disease or condition; slowing or arresting the development of one or more symptom associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition); and relieving the disease, such as by causing the regression of clinical symptoms (e.g., ameliorating the disease state, enhancing the effect of another medication, delaying the progression of the disease, increasing the quality of life, and / or prolonging survival).

[0030] As used herein, “delaying” development of a disease or condition means to defer, hinder, slow, retard, stabilize and / or postpone development of the disease or condition. This delay can be of varying lengths of time, depending on the history of the disease and / or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease or condition.

[0031] As used herein, the term “therapeutically effective amount” or “effective amount” intends such amount of a compound of the disclosure or a pharmaceutically salt thereof sufficient to effect treatment when administered to an individual. As is understood in the art, an effective amount may be in one or more doses, e.g., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved.

[0032] As used herein, “unit dosage form” refers to physically discrete units, suitable as unit dosages, each unit containing a predetermined quantity of active ingredient, or compound, which may be in a pharmaceutically acceptable carrier.

[0033] As used herein, by “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects.

[0034] The term “alkyl”, as used herein, refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1-20 carbons (i.e., Ci-2oalkyl), 1-16 carbons (i.e., Ci-iealkyl), 1-12 carbons (i.e., Ci-nalkyl), 1-10 carbons (i.e., Ci-ioalkyl), 1-8 carbons (i.e., Cisalkyl), 1-6 carbons (i.e., Ci-ealkyl), 1-4 carbons (i.e., Ci-4alkyl), or 1-3 carbons (i.e., Ci-3alkyl). Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, iso-pentyl, neo-pentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or molecular formula, all positional isomers having that number of carbon atoms may be encompassed—for example, “butyl” includes n-butyl, sec-butyl, iso-butyl, and tert-butyl; and “propyl” includes n-propyl and iso-propyl. Certain commonly used alternative names may be used and will be understood by those of ordinary skill in the art. For instance, a divalent group, such as a divalent “alkyl” group, may be referred to as an “alkylene”.

[0035] The term “alkoxy”, as used herein, refers to an -O-alkyl moiety. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, / / -propoxy, Ao-propoxy, / / -butoxy, lerl-butoxy, sec-butoxy, / / -pentoxy, / / -hexoxy, and 1,2-dimethylbutoxy.

[0036] The term “aryl”, as used herein, refers to a fully unsaturated carbocyclic ring moiety. The term “aryl” encompasses monocyclic and polycyclic fused-ring moieties. As used herein, aryl encompasses ring moieties comprising, for example, 6 to 20 annular carbon atoms (i.e., Ce-2oaryl), 6 to 16 annular carbon atoms (i.e., Ce-iearyl), 6 to 12 annular carbon atoms (i.e., Ce- naryl), or 6 to 10 annular carbon atoms (i.e., Ce-ioaryl). Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, fluorenyl, and anthryl.

[0037] The term “cycloalkyl”, as used herein, refers to a saturated or partially unsaturated carbocyclic ring moiety. The term “cycloalkyl” encompasses monocyclic and polycyclic ring moieties, wherein the polycyclic moieties may be fused, branched, or spiro. Cycloalkyl includes cycloalkenyl groups, wherein the ring moiety comprises at least one annular double bond. Cycloalkyl includes any polycyclic carbocyclic ring moiety comprising at least one non-aromatic ring, regardless of the point of attachment to the remainder of the molecule. As used herein, cycloalkyl includes rings comprising, for example, 3 to 20 annular carbon atoms (i.e., a C3-2ocycloalkyl), 3 to 16 annular carbon atoms (i.e., a C3-i6cycloalkyl), 3 to 12 annular carbon atoms (i.e., a C3-i2cycloalkyl), 3 to 10 annular carbon atoms (i.e., a C3-iocycloalkyl), 3 to 8 annular carbon atoms (i. e., a C3-scycloalkyl), 3 to 6 annular carbon atoms (i.e., a C3-6cycloalkyl), or 3 to 5 annular carbon atoms (i.e., a C3-5cycloalkyl). Monocyclic cycloalkyl ring moieties include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantyl, norbomyl, decalinyl, 7,7-dimethyl -bicyclo [2.2.1]heptanyl, and the like. Still further, cycloalkyl also includes spiro cycloalkyl ring moieties, for example, spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro [5.5]undecanyl.

[0038] The term “halo”, as used herein, refers to atoms occupying group VIIA of The Periodic Table and includes fluorine (fluoro), chlorine (chloro), bromine (bromo), and iodine (iodo).

[0039] The term “heteroaryl”, as used herein, refers to an aromatic (fully unsaturated) ring moiety that comprises one or more annular heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term “heteroaryl” includes both monocyclic and polycyclic fused-ring moieties. As used herein, a heteroaryl comprises, for example, 5 to 20 annular atoms (i.e., a 5-20 membered heteroaryl), 5 to 16 annular atoms (i.e., a 5-16 membered heteroaryl), 5 to 12 annular atoms (i.e., a 5-12 membered heteroaryl), 5 to 10 annular atoms (i.e., a 5-10 membered heteroaryl), 5 to 8 annular atoms (i.e., a 5-8 membered heteroaryl), or 5 to 6 annular atoms (i.e., a 5-6 membered heteroaryl). Any monocyclic or polycyclic aromatic ring moiety comprising one or more annular heteroatoms is considered a heteroaryl, regardless of the point of attachment to the remainder of the molecule (i. e., the heteroaryl moiety may be attached to the remainder of the molecule through any annular carbon or any annular heteroatom of the heteroaryl moiety). Examples of heteroaryl groups include, but are not limited to, acridinyl, benzimidazolyl, benzindolyl, benzofuranyl, benzonaphthofuranyl, benzoxazolyl, benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl, furanyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, triazolyl, tetrazolyl, and triazinyl. Examples of the fused-heteroaryl rings include, but are not limited to, quinolinyl, isoquinolinyl, benzo[b]thiophenyl, indazolyl, benzo[d]imidazolyl, pyrazolo[l,5-a]pyridinyl, and imidazo[l,5-a]pyridinyl, wherein the heteroaryl can be bound via either ring of the fused system.

[0040] The term “heterocyclyl”, as used herein, refers to a saturated or partially unsaturated cyclic moiety that encompasses one or more annular heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term “heterocyclyl” includes both monocyclic and polycyclic ring moieties, wherein the polycyclic ring moieties may be fused, bridged, or spiro. Any non-aromatic monocyclic or polycyclic ring moiety comprising at least one annular heteroatom is considered a heterocyclyl, regardless of the point of attachment to the remainder of the molecule (i.e., the heterocyclyl moiety may be attached to the remainder of the molecule through any annular carbon or any annular heteroatom of the heterocyclyl moiety). Further, the term heterocyclyl is intended to encompass any polycyclic ring moiety comprising at least one annular heteroatom wherein the polycyclic ring moiety comprises at least one nonaromatic ring, regardless of the point of attachment to the remainder of the molecule. As used herein, a heterocyclyl comprises, for example, 3 to 20 annular atoms (i.e., a 3-20 membered heterocyclyl), 3 to 16 annular atoms (z.e., a 3-16 membered heterocyclyl), 3 to 12 annular atoms (i.e., a 3-12 membered heterocyclyl), 3 to 10 annular atoms (i.e., a 3-10 membered heterocyclyl), 3 to 8 annular atoms (i.e., a 3-8 membered heterocyclyl), 3 to 6 annular atoms (i.e., a 3-6 membered heterocyclyl), 3 to 5 annular atoms (i.e., a 3-5 membered heterocyclyl), 5 to 8 annular atoms (i.e., a 5-8 membered heterocyclyl), or 5 to 6 annular atoms (i.e., a 5-6 membered heterocyclyl). Examples of heterocyclyl groups include, e.g., azetidinyl, azepinyl, benzodioxolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiophenyl (i.e., thienyl), thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Examples of spiro heterocyclyl rings include, but are not limited to, bicyclic and tricyclic ring systems, such as oxabicyclo[2.2.2]octanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-l-azaspiro[3.3]heptanyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be bound via either ring of the fused system.

[0041] The terms “optional” and “optionally”, as used herein, mean that the subsequently described event or circumstance may or may not occur and that the description includes instances where the event or circumstance occurs and instances where it does not. Accordingly, the term “optionally substituted” infers that any one or more (e.g., 1, 2, 1 to 5, 1 to 3, 1 to 2, etc.) hydrogen atoms on the designated atom or moiety or group may be replaced or not replaced by an atom or moiety or group other than hydrogen. By way of illustration and not limitation, the phrase “methyl optionally substituted with one or more chloro” encompasses -CEE, -CH2CI, -CHCh, and -CCh moieties.

[0042] It is understood that aspects and embodiments described herein as “comprising” include “consisting of’ and “consisting essentially of’ embodiments.

[0043] The term “pharmaceutically acceptable salt”, as used herein, of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” include, for example, salts with inorganic acids, and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Such compositions are well known in the pharmaceutical art. See, e.g., Handbook of Pharmaceutical Salts Properties, Selection, and Use, International Union of Pure and Applied Chemistry, John Wiley & Sons (2008), which is incorporated herein by reference. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, trifluoroacetic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl), amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0044] Isotopically labeled forms of the compounds depicted herein may be prepared. Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2H, 3H, nC, 13C, 14C, 13N, 15N, 15O, 17O, 18O,31P, 32P, 35S, 18F, 36C1, 123I, and 125I, respectively. In some embodiments, a compound of formula (I), or formula (I’) is provided wherein one or more hydrogen is replaced by deuterium or tritium.

[0045] Some of the compounds provided herein may exist as tautomers. Tautomers are in equilibrium with one another. By way of illustration, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds of this disclosure are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, for example, amide-containing compounds are understood to include their imidic acid tautomers. Likewise, imidic-acid containing compounds are understood to include their amide tautomers.

[0046] Also provided herein are prodrugs of the compounds depicted herein, or a pharmaceutically acceptable salt thereof. Prodrugs are compounds that may be administered to an individual and release, in vivo, a compound depicted herein as the parent drug compound. It is understood that prodrugs may be prepared by modifying a functional group on a parent drug compound in such a way that the modification is cleaved in vivo to release the parent drug compound. The development of prodrug compounds is well known in the pharmaceutical art. See, e.g., Rautio, J., Kumpulainen, H., Heimbach, T. et al. Prodrugs: design and clinical applications. Nat. Rev. Drug. Discov. 7, 255-270 (2008), which is incorporated herein by reference.

[0047] The compounds of the present disclosure, or their pharmaceutically acceptable salts, may include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (5)- (or as (D)- or (L)- for amino acids). The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms and mixtures thereof in any ratio. Optically active (+) and (-), (R)- and (5)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or may be resolved using conventional techniques, for example, chromatography and / or fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or the resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC) or chiral supercritical fluid chromatography (SFC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless specified otherwise, it is intended that the present disclosure includes both E and Z geometric isomers. Likewise, cis- and trans- are used in their conventional sense to describe relative spatial relationships.

[0048] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds, but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers, or mixtures thereof, and includes “enantiomers,” which refers to two stereoisomers whose structures are non-superimposable mirror images of one another. “Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror images of each other.

[0049] Where enantiomeric and / or diastereomeric forms exist of a given structure, flat bonds indicate that all stereoisomeric forms of the depicted structure may be present, e.g.,

[0050] Where enantiomeric forms exist of a given structure, flat bonds and the presence of a “ * ” symbol indicate that the composition is made up of at least 90%, by weight, of a single isomer with unknown absolute stereochemistry, e.g.,

[0051] Where enantiomeric and / or diastereomeric forms exist of a given structure with two or more stereocenters, flat bonds and the presence of two or more “ * ” symbols indicate the composition is made up of at least 90%, by weight, of a single enantiomer or diastereomer with unknown absolute stereochemistry, e.g., H ci

[0052] Where enantiomeric and / or diastereomeric forms exist of a given structure, the composition is made up of at least 90%, by weight, dashes or wedges indicate a single enantiomer or diastereomer with known relative or absolute stereochemistry, e.g

[0053] Abbreviations used are those conventional in the art and are in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed, hereby incorporated herein by reference in its entirety. The following examples are intended to be illustrative only and not limiting in any way. °C degrees Celsius HL microliter qW micro wave [M+XX]+ observed mass AC50 half-maximal activity concentration AC2O acetic anhydride AIBN azobi si sobutyronitrile app apparent (NMR) br broad (NMR) BH3 THF borane-tetrahydrofuran complex BBn boron tribromide BnCl benzyl chloride B(Pin)2 bis(pinacolato)diboron Calc’d calculated Cbz-Cl benzyl chloroformate CCh carb ontetrachl ori de CDI carbonyldiimidazole CHCh chloroform CO2 carbon dioxide CS2CO3 cesium carbonate Cui copper iodide d deuterated (NMR solvents) d doublet (NMR) dd doublet of doublets (NMR) DAST diethylaminosulfur trifluoride DMA MA-dimethylacetamide DCE 1,2-di chloroethane DCM dichloromethane DIAD diisopropyl azodi carb oxy late DIEA A,A-diisopropylethylamine DME di methoxy ethane DMEDA A,A-dimethylethylenediamine DMA dimethylacetamide DMF A,A-dimethylformamide DPPF 1,1'- bis(diphenylphosphino)ferrocene EC50 half-maximal effective concentration EDCI l-ethyl-3-(3- dimethylaminopropyl)carbodiim ide Et3N tri ethyl amine EtOAc ethyl acetate EtOH ethanol g grams h hours H hydrogen H2 hydrogen gas H2O water H2O2 hydrogen peroxide HATU N-[(Dimethylamino)-lH-l,2,3-triazolo-[4,5-b]pyridin-1 -ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide HC1 hydrochloric acid HOBt hydroxybenzotri azole HPLC high-performance liquid chromatography In vacuo in a vacuum (Ir[dF(CF 3)ppy]2(dt bpy))PFe [4,4'-Bis(l,l-dimethylethyl)-2,2'-bipyridine-N 1 ,N1 ']bi s [3,5 -difluoro-2-[5-(trifluoromethyl)-2-pyridinyl-N]phenyl-C]Iridium(III) hexafluorophosphate IUPAC International Union of Pure and Applied Chemistry J J-coupling value (NMR) K2CO3 potassium carbonate KI potassium iodide KOAc potassium acetate KOH potassium hydroxide LiAlH4 lithium aluminum hydride LiHMDS lithium bis(trimethylsilyl)amide LiOH lithium hydroxide MeOH methanol MeCN acetonitrile MHz megahertz m multiplet (NMR) mg milligrams min minutes mL milliliter mmol millimole mM millimolar M molarity or molar m-CPBA meta-chloroperoxybenzoic acid MeCN acetonitrile MeSO2Na sodium methanesulfmate MS mass spectrometry MsCl methanesulfonyl chloride Ms2O methanesulfonic anhydride MTBE methyl tert-butyl ether n / a not applicable NaBH(O Ac)3 sodium triacetoxyborohydride NaH sodium hydride NBS A-bromosuccinimide NH4 ammonium nh4oh ammonium hydroxide NH4HCO3 ammonium bicarbonate Na2SO4 sodium sulfate NaBH3C N sodium cyanoborohydride NMP 1 -methyl-2-pyrrolidinone NMR nuclear magnetic resonance NaIO4 sodium periodate NaOH sodium hydroxide OsO4 osmium tetraoxide Pd / C palladium on carbon PCy3 tricyclohexylphosphine Pd2(dba)3 tris(dibenzylideneacetone)dipall adium(O) Pd(PPh3)2 bis(triphenylphosphine)palladiu m(II) chloride Pd(dba)3 tris(dibenzylideneacetone)dipall adium(O) pH potential of hydrogen PPh3 triphenyl phosphine PSI pounds per square inch s singlet (NMR) SEMC1 (2- chloromethoxyethyl)trimethylsil ane SFC super fluid chromatography SOC12 thionyl chloride t triplet (NMR) T3P propanephosphonic acid anhydride TBAB tetrabutylammonium bromide TBAI tetrabutylammonium iodide TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TMSC1 trimethyl silyl chloride Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene Zn(CN)2 zinc cyanide COMPOUNDS

[0054] Provided herein is a compound of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-ealkoxy, and Ci-ealkyl, wherein the Ci-ealkoxy of R1 is optionally substituted with one or more halo, and the Ci-ealkyl of R1 is optionally substituted with one or more halo; R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more deuterium, halo, -OH, -NH2, or Ci-ealkoxy, and the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH; R3, if present, is Ci-ealkyl; L1 is Ci-ealkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more deuterium or Ci-ealkyl, and wherein the Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy; L2 is O or N(RX), wherein Rx is H or Ci-ealkyl; and either (1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl, the Ci-ealkylene of L3 is optionally substituted with one or more -OH or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, and the 3-10 membered heterocyclyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl; X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra; (ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl; (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, (iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-6 alkyl, or 3-10 membered heterocycle, wherein the 3-10 membered heterocycle of Re is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH , oxo or -S(O)2Ra, (vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl), (viii) -CN, (ix) -(CH2)?OH, wherein q is an integer from 0-6, (x) -C(O)-Ci-ealkyl, or (xi) -P(O)(Ci-6alkyl)2; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-6alkyl, -C(O)-Ci-6alkyl, -C(0)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, and wherein the C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH and the C3-iocycloalkyl of Rb is optionally substituted with one or more - OH, C3-iocycloalkyl, or Ci-ealkyl, and wherein the Ci-ealkyl of the C3-iocycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium, or halo, and the 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and the 3-10 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and wherein the Ci-ealkyl of the 3-10 membered heterocyclyl of Rc is further optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-ealkyl, (ii) C3-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, (iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, or (iv) NH(Ci-ealkyl); R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo or -OH, and the Ci-ealkoxy of R5 is optionally substituted with one or more halo; X3 is N or C(R6); X4 is N or C(R7); and R6 and R7 are each independently H or halo.

[0055] Provided herein is a compound of formula (I’): R2 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-ealkoxy, or Ci-ealkyl, wherein the Ci-ealkoxy of R1 is optionally substituted with one or more halo, and the Ci-ealkyl of R1 is optionally substituted with one or more halo; R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more halo, -OH, -NH2, or Ci-ealkoxy, and the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH; R3, if present, is Ci-ealkyl; L1 is Ci-ealkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more Ci-ealkyl, and wherein the Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy; L2 is O or N(RX), wherein Rx is H or Ci-ealkyl; and either (1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl is optionally substituted with one or more -OH or Ci-ealkyl, the Ci-ealkylene of L3 is optionally substituted with one or more -OH or Ci-ealkyl, and the 3-10 membered heterocyclyl is optionally substituted with one or more -OH; X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra; (ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl; (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, C1-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, (iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, C1-6 alkyl, or 3-10 membered heterocycle, wherein the 3-10 membered heterocycle is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH, oxo or -S(O)2Ra, (vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl), (viii) -CN, (ix) -(CH2)?OH, wherein q is an integer from 0-6, (x) -C(O)-Ci-ealkyl, or (xi) -P(O)(Ci-6alkyl)2; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4 and the atoms to which they are attached to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of halo, oxo, Ci-6alkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, and wherein the C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH and the C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, C3-wcycloalkyl, or Ci-ealkyl, and wherein the Ci-ealkyl of the C3-iocycloalkyl of Rb is further optionally substituted with one or more -OH, and the 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-wcycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and the 3-10 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and wherein the Ci-ealkyl of the 3-10 membered heterocyclyl of Rc is further optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl, (ii) Cs-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, or (iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl; R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-6alkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy of R5 is optionally substituted with one or more halo; and R6 and R7 are each independently H or halo.

[0056] Provided herein is a compound of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m is an integer from 0 to 4; n is an integer from 0 to 2; p is an integer from 0 to 10; R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-ealkoxy or -Ci-ealkyl, wherein the Ci-ealkoxy of R1 is optionally substituted with one or more halo, and the Ci-ealkyl of R1 is optionally substituted with one or more halo; R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more halo, -OH, -NH2, or Ci-ealkoxy, and the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH; R3, if present, is Ci-ealkyl; L1 is Ci-ealkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more Ci-ealkyl, and wherein the Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy; L2 is O or N(RX), wherein Rx is H or Ci-ealkyl; and either (1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more Ci-ealkyl, and the 3-10 membered heterocyclyl is optionally substituted with one or more -OH; X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra, (ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl, (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, C1-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, (iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-6 alkyl, or 3-10 membered heterocycle, wherein the 3-10 membered heterocycle is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl or oxo, (vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl), or (viii) -CN; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4 and the atoms to which they are attached to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of halo, oxo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, or -S(O)2-Ci-ealkyl, and the C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, and the 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-wcycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, and the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl, or (ii) C3-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, or (iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl; R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy is optionally substituted with one or more halo; and R6 and R7 are each independently H or halo.

[0057] Any embodiments provided herein of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, are also embodiments of a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0058] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is an integer from 0 to 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more halo, -OH, -NH2, or Ci-ealkoxy, and the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH. In some embodiments, R2 is H, Ci-3alkyl, C3-ecycloalkyl, or 3-6 membered heterocyclyl, wherein the Ci-3alkyl of R2 is optionally substituted with one or more halo, -OH, -NH2, or Ci-3alkoxy, and the C3-6cycloalkyl of R2 is optionally substituted F / ,F with one or more -OH. In some embodiments, R2 is selected from the group consisting of H,*^ F , OH In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof

[0060] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H, Ci-ealkyl, C3-wcycloalkyl, or 3-15 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more deuterieum, halo, -OH, -NH2, or Ci-ealkoxy, and the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH. In some embodiments, R2 is H, Ci-3alkyl, C3-ecycloalkyl, or 3-6 membered heterocyclyl, wherein the Ci-3alkyl of R2 is optionally substituted with one or more deuterieum, halo, -OH, -NH2, or Ci-3alkoxy, and the C3-6cycloalkyl of R2 is optionally substituted with one or more -OH. In some embodiments, R2 is selected from the group consisting of

[0061] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0062] In some embodiments of a compound of formula (I), formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl. In some embodiments, R2 is Ci-3alkyl. In some embodients R2 is methyl or ethyl. In some embodiments, R2 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0063] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl optionally substituted with one or more halo, -OH, -NH2, or Ci-ealkoxy. In some embodiments, R2 is Ci-3alkyl optionally substituted with one or more halo, -OH, -NH2, or Ci-3alkoxy. In some embodiments, R2 is methyl. In some embodiments, R2 is ethyl optionally substituted with one or more halo, -OH, -NH2, F       OH or Ci-ealkoxy. In some embodiments, R2 is selected from the group consisting of and In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0064] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl optionally substituted with one or more deuterium, halo, -OH, -NH2, or Ci-ealkoxy. In some embodiments, R2 is Ci-3alkyl optionally substituted with one or more deuterium, halo, -OH, -NH2, or Ci-3alkoxy. In some embodiments, R2 is methyl. In some embodiments, R2 is ethyl optionally substituted with one or more halo, -OH, -NH2, or Ci-ealkoxy. In some embodiments, R2 is selected from the group D D       F        OH NH2 V-D r— r f /         /               / consisting of                  ,          ,          , and          .

[0065] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is C3-iocycloalkyl, wherein the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH. In some embodiments, R2 is C3-6cycloalkyl, wherein the C3-6cycloalkyl of R2 is optionally substituted with one or more -OH. OH In some embodiments, R2 is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0066] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is 3-15 membered heterocyclyl. In some embodiments, R2 is 3-6 membered heterocyclyl. In some embodiments, R2 is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0067] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 0. In some embodiments m is 1. In some embodiments, m is 2. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0068] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo, -CN, Ci-ealkoxy or -Ci-ealkyl, wherein the Ci-ealkoxy or R1 is optionally substituted with one or more halo, and wherein the Ci-ealkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is halo, -CN, Ci-3alkoxy, or -Ci-3alkyl, wherein the Ci-3alkoxy of R1 is optionally substituted with one or more halo, and wherein the Ci-3alkyl of R1 is optionally substituted with one or more halo. In some F \_F F A       V-F embodiments, R1 is selected from the group consisting of Cl, Br, -CN, methyl, V , and^ . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0069] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo, -CN, Ci-ealkoxy or -Ci-ealkyl, wherein the Ci-ealkoxy or R1 is optionally substituted with one or more halo, and wherein the Ci-ealkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is halo, -CN, Ci-3alkoxy, or -Ci-3alkyl, wherein the Ci-3alkoxy of R1 is optionally substituted with one or more halo, and wherein the Ci-3alkyl of R1 is optionally substituted with one or more halo. In some F \_F embodiments, R1 is selected from the group consisting of Cl, Br, F, I, -CN, methyl, V , and F \^F . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0070] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo. In some embodiments R1 is Cl. In some embodiments, R1 is Br. In some embodiments, R1 is F. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0071] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo. In some embodiments R1 is Cl. In some embodiments, R1 is Br. In some embodiments, R1 is F. In some embodiments R1 is I. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0072] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is Ci-ealkyl, wherein the Ci-ealkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is Cisalkyl, wherein the Ci-3alkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is Ci-3alkyl, wherein the Ci-3alkyl of R1 is optionally substituted with one or more F. In some embodiments, R1 is methyl, wherein the methyl of R1 is optionally substituted with one F VF or more F. In some embodiments, R1 is methyl. In some embodiments, R1 is . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0073] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is -CN. In some variations, theembodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer 44 or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0074] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is Ci-ealkoxy, wherein the Ci-ealkoxy of R1 is optionally substituted with one or more halo. In some embodiments, R1 is Ci-3alkoxy, wherein the Ci-3alkoxy of R1 is optionally substituted with one or more halo. In some embodiments, R1 is Ci-3alkoxy, wherein the Ci-3alkoxy of R1 is optionally substituted with one or more F. In some embodiments, R1 is methoxy, wherein the methoxy of R1 is optionally substituted F \_F with one or more F. In some embodiments, R1 is . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0075] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, / ? is an integer from 0 to 10. In some embodiments, / ? is 0 or 1. In some embodiments, / ? is 0. In some embodiments, / ? is 1. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0076] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R3 is Ci-ealkyl. In some embodiments, R3 is Ci-3alkyl. In some embodiments, R3 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0077] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing (R1 )m and R2 is a 2-indolinone optionally substituted at one or more of positions 1, 5, and 7. In some embodiments, the 2-indolinone ring is unsubstituted. In some embodiments, the 2-indolinone ring is substituted at position 1. In some embodiments, the 2-indolinone ring is substituted at position 5. In some embodiments, the 2-indolinone ring is substituted at position 7. In some embodiments, the 2-indolinone ring is substituted at positions 1, and 5. In some embodiments, the 2-indolinone ring is substituted at positions 5 and 7. In some embodiments, the 2-indolinone ring is substituted at positions 1, 5, and 7. In some embodiments positions 1, 5 and 7 are defined as indicated in the structure, , wherein position 1 is a N atom, each of positions 5 and 7 is a C atom, and ## represent the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0078] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing (R1 )m and R2 wherein ## represents the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0079] In some embodiments of a compound of formula (I), formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing ##   , wherein ## represents the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0080] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing (R1 )m and R2

[0081] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing (R3)Pis ## ## selected from the group consisting of and, wherein ## represents the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0082] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing (R1 )m, R2, and provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0083] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing (R1 )m, R2, and embodiments, the ring bearing (R1)™, R2, and (R3)Pis selected from the group consisting of and               . In some embodiments, the ring bearing (R1)™, R2, and (R3)Pis . In some embodiments, the ring bearing (R1)™, R2, and (R3)Pis              . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0084] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing (R1 )m, R2, and ring bearing (R1)™, R2, and (R3)Pis selected from the group consisting of group consisting of               and               . In some embodiments, the ring bearing . In some embodiments, the ring bearing (R1 )m, R2, and (R3)^ is (R1 )m, R2, and (R3)^ is D D . In some embodiments, the ring bearing (R1 )m, R2, and (R3)^ is

[0085] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is Ci-ealkylene optionally substituted with one or more Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with -OH or Ci-ealkoxy. In some embodiments, L1 is Ci-3alkylene optionally substituted with one or more Ci salkyl, wherein the Ci-3alkyl is optionally substituted with -OH or Ci-3alkoxy. In some embodiments, L1 is methylene. In some embodiments, L1 is ethylene. In some embodiments, L1 is ethylene optionally substituted with one or more Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH or Ci-3alkoxy. In some embodiments, L1 is selected from the group consisting of wherein, for each L1, # denotes the point of attachment to L2 and ## denotes the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0086] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is Ci-6alkylene optionally substituted with one or more deuterieum, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with -OH or Ci-ealkoxy. In some embodiments, L1 is Ci-3alkylene optionally substituted with one or more deuterium, or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with -OH or Ci-3alkoxy. In some embodiments, L1 is methylene. In some embodiments, L1 is ethylene. In some embodiments, L1 is ethylene optionally substituted with one or more deuterium, or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH or Ci-3alkoxy. In some ##               9 D ## , ## i                                                  XX\     /   \ embodiments, L1 is selected from the group consisting of #, D ,      #,      #, ## ## \___ $H , and / wherein, for each L1, # denotes the point of attachment to L2 and ## denotes the point of attachment to the remainder of the molecule.

[0087] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L2 is O or N(RX), wherein Rx is H or Ci-ealkyl. In some embodiments, L2 is O or N(RX), wherein Rx is H or Ci-3alkyl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0088] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L2 is O. In some variations, the embodiments provided herein also apply to a compound of formula (F) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0089] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent or is O, C3-wcycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more Ci-ealkyl, the C3-iocycloalkylof L3 is optionally substituted with one or more -OH, and the 3-10 membered heterocyclyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 absent or is selected from the group consisting of O, In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0090] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent or is O, C3-wcycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl is optionally substituted with one or more -OH, or Ci-ealkyl, the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl, and the 3-10 membered heterocyclyl is optionally substituted with one or more -OH. In some embodiments, L3 absent or is selected from the group consisting of O, 4 4 F- jJr 4 44^4 ,,,,,, ,,,,, embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0091] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent or is O, C3-wcycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH, or Ci-ealkyl; the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl wherein the Ci-ealkyl is optionally substituted with one or more -OH; and the 3-10 membered heterocyclyl is optionally substituted with one or more -OH or Ci-ealkyl. In some embodiments, L3 absent or is selected from the group consisting of O,

[0092] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0093] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is O. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0094] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene. In some embodiments, L3 is Ci-3alkylene. In some embodiments, L3 is selected from the group consisting of , and . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0095] In some embodiments of a compound of formula (I), formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl. In some embodiments, L3 is Ci-3alkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl. In some embodiments, L3 is selected from the group consisting of variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0096] In some embodiments of a compound of formula (II) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl wherein the Ci-ealkyl is optionally substituted with one or more -OH. In some embodiments, L3 is Ci-3alkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl. In some

[0097] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is C3-iocycloalkyl, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is C3-scycloalkyl, wherein the C3-scycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is selected from the group consisting of , and             . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0098] In some embodiments of a compound of formula (I’), (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is C3-iocycloalkyl, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is C3-scycloalkyl, wherein the C3-scycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is selected from the group consisting of 7x1                             OH x- , _L , x. , and X         jn some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0099] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl. In some embodiments, L3 is 3-6 membered heterocyclyl. In some embodiments, L3 is selected from the group consisting of and . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0100] In some embodiments of a compound of formula (I), formula (I’) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl. In some embodiments, L3 is 3-6 membered heterocyclyl. In some embodiments, L3 is selected from the group consisting of o In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0101] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl. In some embodiments, L3 is 3-6 membered heterocyclyl. In some embodiments, L3 is

[0102] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing R4 is -S(O)2-Ra, 5-20 membered heteroaryl, -N(Rd)2, -NS(O)-(Ci-6alkyl)2, -C(O)-N(Re)2, 3-10 membered heterocyclyl, -S(O)(N-Ci-6alkyl)-(Ci-6alkyl), or -CN. In some embodiments, R4 is S(O)2-Ra, 5-10 membered heteroaryl, -N(Rd)2, -NS(O)-(Ci-3alkyl)2, -C(O)-N(Re)2, 3-6 membered heterocyclyl, -S(O)(N-Ci-3alkyl)-(Ci-3alkyl), or -CN. In some embodiments, R4 is selected from the group consisting of -NH2, some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0103] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing R4 is -S(O)2-Ra, 5-20 membered heteroaryl, -N(Rd)2, -NS(O)-(Ci-6alkyl)2, -C(O)-N(Re)2, 3-10 membered heterocyclyl, -S(O)-N(Ci-6alkyl)-(Ci-6alkyl), -CN, -(CH2)?OH, -C(O)-Ci-6alkyl, or -P(O)(Ci-6alkyl)2. In some embodiments, R4 is S(O)2-Ra, 5-10 membered heteroaryl, -N(Rd)2, -NS(O)-(Ci-3alkyl)2, -C(O)-N(Re)2, 3-6 membered heterocyclyl, -S(O)(N-Ci-3alkyl)-(Ci-3alkyl), -CN, -OH, -CH2OH, -C(O)-Ci-3alkyl, or -P(O)(Ci-3alkyl)2. In some embodiments, R4 is selected from the group consisting of -NH2, X* 0 ^-0 / 40 v '° / oA °* )— F \ -CN, -OH, -CH2OH, -C(O)-N(CH3)2,   \ ,            / , F nd Hd , / 4o thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-3alkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-salkyl, or -N(Ci-3alkyl)-C(O)-Ci-3alkyl. In some embodiments, R4 is selected from the group consisting of °' \ embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0105] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-3alkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-salkyl, or -N(Ci-3alkyl)-C(O)-Ci-3alkyl. In some embodiments, R4 is selected from the group

[0106] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is C3-iocycloalkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is C3-iocycloalkyl optionally substituted with one or more -OH, C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-6alkyl)2,-C(0)-C3-ioheterocyclyl or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is C3-6cycloalkyl optionally substituted with one or more -OH, C(O)2-Ci-6alkyl, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -C(O)-C3-wheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is C3-6cycloalkyl optionally substituted with one or more -OH, C(O)2-Ci-3alkyl, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -C(O)-C3-6heterocyclyl, or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH. In some , and . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0107] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is 3-10 membered heterocyclyl. In some embodiments R4 is -S(O)2-Ra, wherein Ra is 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is 3-6 membered heterocyclyl optionally substituted with one or more Ci-ealkyl. In some embodiments, wherein R4 is -S(O)2-Ra, wherein Ra is 3-6 membered heterocyclyl optionally \ / ^° substituted with one or more Ci-3alkyl. In some embodiments, R4 is °     . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0108] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is 5-20 membered heteroaryl. In some embodiments, R4 is 5-20 membered heteroaryl optionally substituted with one or more Ci-ealkyl. In some embodiments, R4 is 5-6 membered heteroaryl optionally substituted with one or more Ci-ealkyl. In some embodiments, R4 is 5-6 membered heteroaryl optionally substituted with one or more Ci-3alkyl. In some embodiments, R4 is 5-6 membered heteroaryl optionally substituted with one or more methyl. In some embodiments, R4 is selected from the group consisting in of N , N , and 0   . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0109] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4is -N(Rd)2, wherein each of Rd is independently H, Ci-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, and wherein Ra is Ci-ealkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is independently H, C1-3 alkyl, or -S(O)2-Ra, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH, and wherein Ra is Ci-3alkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is independently H, C1-6 alkyl, or -S(O)2-Ra, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH, and wherein Ra is methyl. In some embodiments, R4 is o oo ^,8                J;S '—OH selected from the group consisting of -NH2,        ,    \ , and \         . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0110] In some embodiments of a compound of formula (I), formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -N(Rd)2, wherein each of Rd is independently H, C1-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, and wherein Ra is Ci-ealkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is independently H, C1-3 alkyl, or -S(O)2-Ra, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH, and wherein Ra is Ci-3alkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is independently H, C1-6 alkyl, or -S(O)2-Ra, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH, and wherein Ra is methyl. In some embodiments, R4 is selected from the group consisting of -NH2, /   , °' \ and In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0111] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or C1-6 alkyl. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or C1-3 alkyl. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or methyl. In some embodiments, R4 is -C(O)-NH2. In some embodiments, R4 is -C(O)-NH(CH3). In some embodiments, R4 is -C(O)-N(CH3)2. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0112] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or 3-10 membered heterocycle, wherein the 3-10 membered heterocycle is optionally substituted with one or more oxo. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or 3-6 membered heterocycle, wherein the 3-6 membered heterocycle is optionally substituted with one or more oxo. In some embodiments, R4 is P Q selected from the group consisting of ° , and °   . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0113] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl. In some embodiments R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, -NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-7 membered heterocyclyl, wherein the 3-7 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, NH-S(O)2-Ra, or -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-7 membered heterocyclyl, wherein the 3-7 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, -NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, wherein Ra is methyl. In some embodiments, R4 is selected from the group consisting of In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0114] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is 3-10 membered heterocyclyl optionally substituted with one or more oxo or Ci-ealkyl. In some embodiments, R4 is 3-7 membered heterocyclyl optionally substituted with one or more oxo or Ci-ealkyl. In some embodiments, R4 is 3-7 membered heterocyclyl optionally substituted with one or more oxo or Ci- X o X ° W ^=o 3alkyl. In some embodiments, R4 is selected from the group consisting of ,         , and 0 . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0115] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH, oxo or -S(O)2Ra. In some embodiments, R4 is 3-7 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH, oxo or -S(O)2Ra. In some embodiments, R4 is 3-7 membered heterocyclyl optionally substituted with one or more Ci-3alkyl, -OH, oxo or -S(O)2Ra. In some embodiments, R4 is selected from the group consisting of variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0116] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH, oxo or -S(O)2Ra. In some embodiments, R4 is 3-7 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH, oxo or -S(O)2Ra. In some embodiments, R4 is 3-7 membered heterocyclyl optionally substituted with one or more Ci-3alkyl, -OH, oxo or -S(O)2Ra. In some embodiments, R4 is selected from the . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0117] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH , oxo or -S(O)2Ra. In some embodiments, R4 is 3-7 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH, oxo or -S(O)2Ra. In some embodiments, R4 is 3-7 membered heterocyclyl optionally substituted with one or more Ci-3alkyl, -OH, oxo or -S(O)2Ra. In some embodiments, R4 is selected from the and /    .

[0118] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -NS(O)-(Ci-6alkyl)2. In some embodiments, R4 is -NS(O)-(Ci-3alkyl)2. In some embodiments, R4 is I .

[0119] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)(N-Ci-6alkyl)-(Ci-ealkyl). In some embodiments, R4 is -S(O)(N-Ci-3alkyl)-(Ci-3alkyl). In some embodiments, R4 is I . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0120] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0121] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -(CIL^OH, wherein q is an integer from 0-6. R4 is -(CH2)?OH, wherein q is an integer from 0-2. In some embodiments, R4 is -OH. In some embodiments, R4 is selected from the group consisting of , and^H. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0122] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-Ci-6alkyl. In some embodiments, R4 is -C(O)-Ci-3alkyl. In some embodiments, R4 is -C(O)CH3. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0123] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -P(O)(Ci-6alkyl)2. In some embodiments, R4 is -P(O)(Ci-3alkyl)2. In some embodiments, R4 is -P(O)(CH3)2. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0124] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, each of X1 and X2 is independently N or C(R5). In some embodiments, each of X1 and X2 is N. In some embodiments, each of X1 and X2 is C(R5). In some embodiments, one of X1 and X2 is CR5, and the other of X1 and X2 is N. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0125] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1 and X2 is CR5, and the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl optionally substituted with one or more of Rb. In some embodiments, one of X1 and X2 is CR5, and the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form a 5-8 membered heterocyclyl optionally substituted with one or more of Rb. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0126] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is halo, oxo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, or -S(O)2-Ci-ealkyl, and the C3-iocycloalkyl of Rb is optionally substituted with one or more -OH. In some embodiments, Rb is halo, oxo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rb is optionally substituted with one or more halo, OH, or -S(O)2-Ci-3alkyl, and the C3-ecycloalkyl of Rb is optionally substituted with one or more -OH. In some embodiments, also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0127] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is, independently at each occurrence, selected from the group consisting of halo, oxo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, wherein the C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH, and the C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, C3-iocycloalkyl, or Ci-ealkyl, wherein the Ci-ealkyl of the C3-wcycloalkyl of Rb is further optionally substituted with one or more -OH. In some embodiments, Rb is, independently at each occurrence, selected from the group consisting of halo, oxo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-3alkyl, or C3-6cycloalkyl, wherein the C3-ecycloalkyl of the Ci-3alkyl of Rb is further optionally substituted with one or more Ci-3alkyl or -OH, and the C3-ecycloalkyl of Rb is optionally substituted with one or more -OH, C3-6cycloalkyl, or Ci-3alkyl, wherein the Ci-3alkyl of the C3-6cycloalkyl of Rb is further optionally substituted with one or more -OH. In some embodiments, Rb is selected from the group consisting of oxo, -S(O)2CH3,   \ /   , F , also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0128] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is, independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-ealkyl, -C(O)-Ci-ealkyl, -C(O)-NH2, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, wherein the C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH, and the C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, C3-iocycloalkyl, or Ci-ealkyl, wherein the Ci-ealkyl of the C3-wcycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium, or halo. In some embodiments, Rb is, independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-3alkyl, or C3-6cycloalkyl, wherein the Cs-ecycloalkyl of the Ci-3alkyl of Rb is further optionally substituted with one or more Ci-3alkyl or -OH, and the C3-ecycloalkyl of Rb is optionally substituted with one or more -OH, C3-ecycloalkyl, or Ci-3alkyl, wherein the Ci-3alkyl of the C3-ecycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium or halo. In some embodiments, Rb is selected from the group consisting of - , and

[0129] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is oxo. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0130] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is Ci-ealkyl. In some embodiments, Rb is Ci-ealkyl optionally substituted with one or more halo, OH, or -S(O)2-Ci-6alkyl. In some embodiments, Rb is Ci-3alkyl optionally substituted with one or more more halo, OH , or - S(O)2-Ci-3alkyl. In some embodiments, Rb is selected from the group consisting of In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0131] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is Ci-ealkyl. In some embodiments, the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, wherein the C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH. In some embodiments, Rb is Ci-3alkyl optionally substituted with one or more halo, OH, -S(O)2-Ci-3alkyl, or C3-6cycloalkyl, wherein the C3-ecycloalkyl of the Ci-3alkyl of Rb is further optionally substituted with one or more Ci-3alkyl or -OH. In some embodiments, Rb is selected from the group consisting of herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0132] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is Ci-ealkyl. In some embodiments, the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, wherein the C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH. In some embodiments, Rb is Ci-3alkyl optionally substituted with one or more halo, OH, -S(O)2-Ci-3alkyl, or C3-6cycloalkyl, wherein the Cs-ecycloalkyl of the Ci-3alkyl of Rb is further optionally substituted with one or more Ci-3alkyl or -OH. In some embodiments, Rb is selected from the group consisting of \      ,       , F ,

[0133] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is -C(O)-NH(Ci-6alkyl). In h"^0 some embodiments, Rb is -C(O)-NH(Ci-3alkyl). In some embodiments, Rb is \   . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0134] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is -C(O)-Ci-6alkyl. In some 2=° embodiments, Rb is -C(O)-Ci-3alkyl. In some embodiments, Rb is '    . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0135] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing Rb is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, Rb is -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, Rb is -S(O)2-Ra, Ra is methyl. In some embodiments, Rb is -S(O)2CH3. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0136] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is C3-iocycloalkyl optionally substituted with one or more -OH. In some embodiments, Rb is C3-6cycloalkyl optionally substituted with one or more -OH. In some embodiments, Rb is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0137] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is C3-iocycloalkyl optionally substituted with one or more -OH, C3-iocycloalkyl, or Ci-ealkyl, wherein the Ci-ealkyl is further optionally substituted with one or more -OH. In some embodiments, Rb is C3-6cycloalkyl optionally substituted with one or more -OH, C3-6cycloalkyl, or Ci-3alkyl, wherein the Ci-3alkyl is further optionally substituted with one or more -OH. In some embodiments, Rb is selected from the M l~~l       I—[~OH    U-OH yOH > group consisting of °H,      \   ,      /    ,            ,          , and H°. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0138] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is C3-iocycloalkyl optionally substituted with one or more -OH, C3-iocycloalkyl, or Ci-ealkyl, wherein the Ci-ealkyl is further optionally substituted with one or more -OH, deuterium, or halo. In some embodiments, Rb is C3-6cycloalkyl optionally substituted with one or more -OH, C3-6cycloalkyl, or Ci-3alkyl, wherein the Ci-3alkyl is further optionally substituted with one or more -OH, deuterium, or halo. In some

[0139] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rb is 3-10 membered heterocyclyl. In some embodiments, Rb is 3-6 membered heterocyclyl. In some embodiments, Rb is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0140] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1 and X2 is CR5, and the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heteroaryl. In some embodiments, one of X1 and X2 is CR5, and the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form a 74 5-6 membered heteroaryl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0141] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1 and X2 is CR5, and the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heteroaryl optionally substituted with one or more Rc. In some embodiments one of X1 and X2 is CR5, and the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form a 5-6 membered heteroaryl optionally substituted with one or more Rc. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0142] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rc is halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 310 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, and the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH. In some embodiments, Rc is halo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-ecycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-3alkyl, and the C3-6cycloalkyl of Rc is optionally substituted with one or more -OH. In some embodiments, Rc is selected from the group consisting of methyl, isopropyl, -S(O)2CH3, and         [n some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0143] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rc is independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, - C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-6alkyl, the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH, or Ci-ealkyl, and the 3-10 membered heterocyclyl of Rc is optionally substituted with one or more -OH, or Ci-ealkyl,wherein the Ci-ealkyl is further optionally substituted with one or more -OH. In some embodiments, Rc is independently at each occurrence, selected from the group consisting of halo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rc is optionally substituted with one or more -S(O)2-Ci-3alkyl, the C3-6cycloalkyl of Rc is optionally substituted with one or more -OH, or Ci-3alkyl, and the 3-6 membered heterocyclyl of Rc is optionally substituted with one or more -OH, or Ci-3alkyl,wherein the Ci-3alkyl is further optionally substituted with one or more -OH. In some embodiments, Rc is selected from the group consisting of methyl, isopropyl, -S(O)2CH3, and . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0144] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rc is Ci-ealkyl, -S(O)2-Ra. In some embodiments, Rc is Ci-3alkyl. In some embodiments, Rc is methyl. In some embodiments, Rc is isopropyl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0145] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rc is Ci-ealkyl optionally substituted with one or more -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, Rc is Ci-3alkyl optionally substituted with one or more -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, Rc is Ci-3alkyl optionally substituted with one or more -S(O)2-Ra, wherein Ra is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0146] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rc is C3-iocycloalkyl optionally substituted with one or more -OH. In some embodiments, Rc is C3-6cycloalkyl optionally substituted with one or more -OH. In some embodiments, Rc is . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0147] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rc is C3-iocycloalkyl optionally substituted with one or more -OH, or Ci-ealkyl. In some embodiments, Rc is Cs-ecycloalkyl optionally substituted with one or more -OH, or Ci-3alkyl. In some embodiments, Rc is selected from the group consisting of"^~^,H , and In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0148] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rc is 3-10 membered heterocyclyl optionally substituted with one or more -OH, or Ci-ealkyl, wherein the Ci-ealkyl is further optionally substituted with one or more -OH. In some embodiments, Rc is 3-6 membered heterocyclyl optionally substituted with one or more -OH, or Ci-3alkyl, wherein the Ci-3alkyl is further optionally substituted with one or more -OH. In some embodiments, Rc is selected from the y v group consisting of , °H , and Hc’ . In some variations, the embodiments provided 77 herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0149] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy is optionally substituted with one or more halo. In some embodiments, R5 is independently at each occurrence, H, halo, -CN, 3-6 membered heterocyclyl, Ci-3alkyl, or Ci-3alkoxy, wherein the Ci-3alkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-3alkoxy is optionally substituted with one or more halo. In some embodiments, R5 is selected from the group variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0150] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0151] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is halo. In some embodiments, R5 is Cl, or F. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0152] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0153] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is Ci-ealkyl. In some embodiments, R5 is Ci-3alkyl. In some embodiments, R5 is methyl. In some embodiments, R5 is Ci-ealkyl, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH. In some embodiments, R5 is Ci-3alkyl, wherein the Ci-3alkyl of R5 is optionally substituted with one or more halo, or -OH. In some embodiments, R5 is Ci-3alkyl, wherein the Ci-3alkyl of R5 is optionally substituted with one or more fluoro, or -OH. In some embodiments, R5 is independently selected 'P 'S-f 'S-y. from the group consisting of methyl, F , F F , F F, and H0 DH . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0154] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is 3-10 membered heterocyclyl. In some embodiments, R5 is 3-6 membered heterocyclyl. In some embodiments, R5 is In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0155] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is Ci-ealkoxy optionally substituted with one or more halo. In some embodiments, R5 is Ci-3alkoxy optionally substituted with one or more halo. In some embodiments, R5 is Ci-3alkoxy optionally substituted with one or F—( more fluoro. In some embodiments, R5 is F . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0156] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R6 and R7 are each independently H or halo. In some embodiments, R6 and R7 are each independently H or fluoro. In some embodiments, each of R6 and R7 is H. In some embodiments, each of R6 and R7 is fluoro. In some embodiments, one of R6 and R7 is H and the other of R6 and R7 is fluoro. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0157] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a bi-substituted phenyl with one group bound at the para position relative to the phenyl’s attachment to L2. In some embodiments, the bi-substituted phenyl is selected In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0158] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a bi-substituted phenyl with one group bound at the para position relative to the phenyl’s attachment to L2. In some embodiments, the bi-substituted phenyl is selected some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0159] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a bi-substituted phenyl with one group bound at the para position relative to the phenyl’s attachment to L2. In some embodiments, the bi-substituted phenyl is selected

[0160] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a tri-substituted phenyl with two groups bound at a meta, and the para positions relative to the phenyl’s attachment to L2. In some embodiments, the tri-substituted compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0161] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a tri-substituted phenyl with two groups bound at a meta, and the para positions relative to the phenyl’s attachment to L2. In some embodiments, the tri-substituted

[0162] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a tetra-substituted phenyl with three groups bound at the meta, and para positions relative to the phenyl’s attachment to L2. In some embodiments, the tetra-substituted phenyl is selected from the group consisting of compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0163] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a bi-substituted pyridine with one group bound at the para position relative to the pyridine’s attachment to L2. In some embodiments, the bi-substituted pyridine is In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0164] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a tri-substituted pyridine with two groups bound at the meta, and para positions relative to the pyridine’s attachment to L2. In some embodiments, the tri-substituted pyridine is                 °   . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0165] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a tri-substituted pyridine with two groups bound at the meta, and para positions relative to the pyridine’s attachment to L2. In some embodiments, the tri-substituted the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0166] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a tri-substituted pyridine with two groups bound at the meta, and para positions relative to the pyridine’s attachment to L2. In some embodiments, the tri-substituted pyridine is selected from the group consisting of

[0167] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a bi-substituted pyrimidine with two groups bound at the para position relative to the pyrimidine’s attachment to L2. In some embodiments, the bi-substituted pyrimidine is selected from the group consisting of In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0168] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a bi-substituted pyrimidine with two groups bound at the para position relative to the pyrimidine’s attachment to L2. In some embodiments, the bi-substituted pyrimidine is selected from the group consisting of . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0169] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a bi-substituted pyrimidine with two groups bound at the para position relative to the pyrimidine’s attachment to L2. In some embodiments, the bi-substituted embodiments, the bi-substituted pyrimidine is selected from the group consisting of variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0170] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a bi-substituted pyrimidine with two groups bound at the para position relative to the pyrimidine’s attachment to L2. In some embodiments, the bi-substituted pyrimidine is selected from the group consisting of

[0171] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0172] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0173] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heteroaryl selected from the group consisting of In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0174] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heteroaryl selected from the group consisting of bearing L3, R4, R6, and R7 together form a heteroaryl selected from the group consisting of OH and OH . In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heteroaryl selected from the group consisting of OH OH and . In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heteroaryl selected from the group consisting of OH ■"OH and . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0175] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0176] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of OH OH In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0177] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of . In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of . In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of

[0178] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form OH . In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 together form OH In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 together form variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0179] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing 104 . In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 ___chf2 oh ~V / ^NH            c V] 1—l-OH          >k- CF3    oh \i=^ IN                 , or bearing L3, R4, R6, and R7 together form '—\       F      OH      \ 7 -r d CF3    oh           __CF3    OH 7                                                                                7 -N     OH              OCHF2 OH 7                                                                             7 cf3 oh . In some embodiments, L1, L2, and the ring _ / CF3 cf3    oh o / = /               V-N Vn^ /    ' ^.'OH 7                                                                             7 CHF2 oh         / ~VCF3 '°H 7                                                                                     7

[0180] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0181] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0182] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of and . In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group OH In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 together form OH . In some variations, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heterocycle selected from the group consisting of OH and OH . In certain variations, L1, L2, and the ring bearing L3, R4, R6, and R7 together In certain variations, L1, L2, and the ring bearing L3, R4, R6, and R7 In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0183] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, and R4 together form a heterocycle selected from the group consisting of

[0184] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heteroaryl selected from the group consisting of OH . In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 together form a heteroaryl selected from the group consisting of OH . In some embodiments, L1, L2, and the ring bearing L3, R4, R6, and R7 compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0185] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing embodiments, L1, L2, and the ring bearing R6, and R7 together form or . In some embodiments, L1, L2, and the ring bearing R6, and R7 together

[0186] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1, L2, and the ring bearing R6, and R7 together form a heteroaryl selected from the group consisting of some embodiments, L1, L2, and the ring bearing R6, and R7 together or

[0187] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1 or 2, and L2 is -O-. In some embodiments, n is 2, and L2 is -0-. In some embodiments, n is 1, and L2 is O. In some embodiments, n is 1 or 2, L2 is -O- and R4 is -S(0)2-Ra. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0188] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is l,p is 0, L2 is O and each of X1 and X2 is C(R5), wherein each R5 is independently H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH, and wherein the Ci-ealkoxy of R5 is optionally substituted with one or more halo. In some embodiments, n is l,p is 0, L2 is O and each of X1 and X2 is C(R5), wherein each R5 is independently H. In some embodiments, n is l,p is 0, L2 is O and each of X1 and X2 is C(R5), wherein one of R5 is H and the other of R5 is halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH, and wherein the Ci-ealkoxy is optionally substituted with one or more halo. In some embodiments, n is 1, p is 0, L2 is O and each of X1 and X2 is C(R5), wherein each R5 is independently halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH, and wherein the Ci-ealkoxy is optionally substituted with one or more halo. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0189] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is l,p is 0, L2 is O, one of X1 and X2 is N, and the other of X1 and X2 is C(R5), wherein R5 is H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH, and wherein the Ci-ealkoxy of R5 is optionally substituted with one or more halo. In some embodiments, n is \,p is 0, L2 is O, one of X1 and X2 is N, and the other of X1 and X2 is C(R5), wherein R5 is H. In some embodiments, n is \,p is 0, L2 is O, one of X1 and X2 is N, and the other of X1 and X2 is C(R5), wherein R5 is halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH, and wherein the Ci-ealkoxy of R5 is optionally substituted with one or more halo. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0190] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1, L2 is O, and each of X1 and X2 is N. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0191] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is \,p is 0, L2 is O, one of X1 and X2 is C(R5), wherein R5 is H, the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form (i) a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more of Rb, or (ii) a 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted with one or more Rc, and each of R6 and R7 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0192] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1, L2 is O, one of X1 and X2 is C(R5), wherein R5 is H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH, and wherein the Ci-ealkoxy of R5 is optionally substituted with one or more halo, the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form (i) a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more of Rb, or (ii) a 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted with one or more Rc, and each of R6 and R7 is H. In some embodiments, n is 1, L2 is O, one of X1 and X2 is C(R5), wherein R5 is H, the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form (i) a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more of Rb, or (ii) a 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted with one or more Rc, and each of R6 and R7 is H. In some embodiments, n is 1, L2 is O, one of X1 and X2 is C(R5), wherein R5 is halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH, and wherein the Ci-ealkoxy of R5 is optionally substituted with one or more halo, the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form (i) a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more of Rb, or (ii) a 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted with one or more Rc, and each of R6 and R7 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0193] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is l,p is 0, L2 is O, one of X1 and X2 is N, the other of X1 and X2 is C that is taken together with R4, and the atoms to which they are attached, to form (i) a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more of Rb, or (ii) a 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted with one or more Rc, and each of R6 and R7 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0194] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing: m is an integer from 0 to 2; n is an integer from 1 to 2; p is an integer from 0 to 2; R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-3alkoxy, or Ci-3alkyl, wherein the Ci-3alkoxy of R1 is optionally substituted with one or more halo, and the Ci-3alkyl of R1 is optionally substituted with one or more halo; R2 is H, Ci-3alkyl, C3-6cycloalkyl, or 3-10 membered heterocyclyl, wherein the Ci-3alkyl of R2 is optionally substituted with one or more halo, -OH, -NH2, or Ci-3alkoxy, and the C3-6cycloalkyl of R2 is optionally substituted with one or more -OH; R3, if present, is Ci-3alkyl; L1 is Ci-3alkylene, wherein the Ci-3alkylene of L1 is optionally substituted with one or more Ci-3alkyl, and wherein the Ci-3alkyl is further optionally substituted with one or more -OH or Ci-3alkoxy; L2 is O or N(RX), wherein Rx is H or Ci-3alkyl; and either (1) L3 is absent or is O, C3-6cycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-6cycloalkyl is optionally substituted with one or more -OH, or Ci-3alkyl, the Ci-3alkylene of L3 is optionally substituted with one or more -OH or Ci-3alkyl, and the 3-10 membered heterocyclyl is optionally substituted with one or more -OH; X1 and X2 are each independently N or -C(R5); and R4 is: (i)     -S(O)2-Ra; (ii) 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl of R4 is optionally substituted with one or more Ci-3alkyl; (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-3alkyl, or -S(O)2-Ra, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH, (iv) -NS(O)-(Ci-3alkyl)2, wherein the Ci-3alkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-3alkyl, or 3-10 membered heterocycle, wherein the 3-10 membered heterocycle is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-3alkyl, -OH , oxo or -S(O)2Ra , (vii) -S(O)-N(Ci-3alkyl)-(Ci-3alkyl), (viii) -CN, (ix) -(CH2)?OH, wherein q is an integer from 0-4, (x) -C(O)-Ci-3alkyl, or (xi) -P(O)(Ci-3alkyl)2; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4 and the atoms to which they are attached to form a 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of halo, oxo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-3alkyl, or C3-6cycloalkyl, and wherein the C3-6cycloalkyl of the Ci-3alkyl of Rb is further optionally substituted with one or more Ci-3alkyl or -OH and the C3-6cycloalkyl of Rb is optionally substituted with one or more -OH, C3- ecycloalkyl, or Ci-3alkyl, and wherein the Ci-3alkyl of the C3-6cycloalkyl of Rb is further optionally substituted with one or more -OH, and the 5-10 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-ecycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rc is optionally substituted with one or more -S(O)2-Ci-6alkyl, the C3-6cycloalkyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and the 3-6 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-3alkyl, and wherein the Ci-3alkyl of the 3-6 membered heterocyclyl of Rc is further optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-3alkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-3alkyl, or -N(Ci-3alkyl)-C(O)-Ci-3alkyl, (ii) C3-6cycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-3alkyl, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, or -C(O)-C3-6heterocyclyl, or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH, or (iii) 3-6 membered heterocyclyl optionally substituted with one or more Ci-3alkyl; R5 is, independently at each occurrence, H, halo, -CN, 3-6 membered heterocyclyl, Ci-3alkyl, or Ci-3alkoxy, wherein the Ci-3alkyl of R5 is optionally substituted with one or more halo or -OH, and wherein the Ci-3alkoxy of R5 is optionally substituted with one or more halo; and R6 and R7 are each independently H or halo. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0195] In some embodiments of a compound of formula (I’), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing: m is an integer from 0 to 2; n is an integer from 1 to 2; p is an integer from 0 to 1; R1, if present is, independently at each occurrence selected from the group consisting of Cl, Br, F, I, -CN, Ci-3alkoxy, or Ci-3alkyl, wherein the Ci-3alkoxy of R1 is optionally substituted with one or more F, and the Ci-3alkyl of R1 is optionally substituted with one or more F; R2 is H, Ci-3alkyl, C3-4cycloalkyl, or 3-4 membered heterocyclyl, wherein the Ci-3alkyl of R2 is optionally substituted with one or more F, -OH, -NH2, or -OCH3, and the C3-4cycloalkyl of R2 is optionally substituted with one or more -OH; R3, if present, is Ci-3alkyl; L1 is Ci-3alkylene, wherein the Cwalkylene of L1 is optionally substituted with one or more methyl, and wherein the methyl is further optionally substituted with one or more -OH or -OCH3; L2 is O; and either (1) L3 is absent or is O, C3-4cycloalkyl, 3-7 membered heterocyclyl, or Ci-4alkylene, wherein the C3-4cycloalkyl is optionally substituted with one or more -OH, or -CH3, the Ci-ealkylene of L3 is optionally substituted with one or more -OH, -CH3, and X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra; (ii) 5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl of R4 is optionally substituted with one or more -CH3; (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-3alkyl, or -S(O)2-Ra, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH, 126 (iv) -NS(O)-(CH3)2 (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, CH3, or 3-6 membered heterocycle, wherein the 3-6 membered heterocycle is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-7 membered heterocyclyl, wherein the 3-7 membered heterocyclyl is optionally substituted with one or more F, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-7 membered heterocyclyl optionally substituted with one or more Ci-3alkyl, -OH , oxo or -S(O)2Ra , (vii) -S(O)-N(CH3)-(CH3), (viii) -CN, (ix) -(CH2)?OH, wherein q is an integer from 0-2, or (x)    -C(O)-CH3, or (xi) -P(O)(CH3)2; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4 and the atoms to which they are attached to form a 5-8 membered heterocyclyl or a 5-6 membered heteroaryl, wherein the 5-8 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of oxo, Ci-3alkyl, -C(O)-CH3, -C(O)-NH2, -C(O)-NH(CH3), -C(O)-N(CH3)2, -S(O)2-Ra, C3-4cycloalkyl, and 3-4 membered heterocyclyl, wherein the Ci-3alkyl of Rb is optionally substituted with one or more F, OH, -S(O)2- CH3, or C3-4cycloalkyl, and wherein the C3-4cycloalkyl of the Ci-3alkyl of Rb is further optionally substituted with one or more CH3 or -OH and the C3-4cycloalkyl of Rb is optionally substituted with one or more -OH, C3- 4cycloalkyl, or Ci-3alkyl, and wherein the Ci-3alkyl of the C3-4cycloalkyl of Rb is further optionally substituted with one or more -OH, and the 5-6 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of Ci-3alkyl, -S(O)2-Ra, C3-4cycloalkyl, and 3-4 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-CH3 the C3-4cycloalkyl of Rc is optionally substituted with one or more -OH or Ci-3alkyl, and the 3-4 membered heterocyclyl of Rc is optionally substituted with one or more -OH or methyl, and wherein the methyl of the 3-4 membered heterocyclyl of Rc is further optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-3alkyl optionally substituted with one or more F, -OH, -S(O)2-CH3, or -N(CH3)- C(O)-CH3, (ii) C3-4cycloalkyl optionally substituted with one or more -OH, -C(O)2-CH3, -C(O)-NH(CH3), -C(O)-N(CH3)2, or -C(O)-C3-4heterocyclyl, or methyl, wherein the methyl is optionally substituted with one or more -OH, or (iii) 3-4 membered heterocyclyl optionally substituted with one or more methyl; R5 is, independently at each occurrence, H, Cl, F, -CN, 3-4 membered heterocyclyl, Ci-3alkyl, or Ci-3alkoxy, wherein the Ci-3alkyl of R5 is optionally substituted with one or more F or -OH and wherein the Ci-3alkoxy of R5 is optionally substituted with one or more F; and R6 and R7 are each independently H or F. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0196] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 2; n is an integer from 1 to 2; p is an integer from 0 to 1; R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-3alkoxy, and Ci-3alkyl, wherein the Ci-3alkoxy of R1 is optionally substituted with one or more halo, and the Ci-3alkyl of R1 is optionally substituted with one or more halo; R2 is H, Ci-3alkyl, C3-6cycloalkyl, or 3-6 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more deuterium, halo, -OH, -NH2, or Ci-3alkoxy, and the C3-6cycloalkyl of R2 is optionally substituted with one or more -OH; R3, if present, is Ci-3alkyl; L1 is Ci-3alkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more deuterium or Ci-3alkyl, and wherein the Ci-3alkyl is further optionally substituted with one or more -OH or Ci-3alkoxy; L2 is O; and either (1) L3 is absent or is O, C3-ecycloalkyl, 3-6 membered heterocyclyl, or Ci-3alkylene, wherein the C3-6cycloalkyl of L3 is optionally substituted with one or more -OH or Ci-3alkyl, the Ci-3alkylene of L3 is optionally substituted with one or more -OH or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH, and the 3-6 membered heterocyclyl of L3 is optionally substituted with one or more -OH or Ci-3alkyl; X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra; (ii) 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl of R4 is optionally substituted with one or more Ci-3alkyl; (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-3alkyl, or -S(O)2-Ra, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH, (iv) -NS(O)-(Ci-3alkyl)2, wherein the Ci-3alkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-3alkyl, or 3-6 membered heterocycle, wherein the 3-6 membered heterocycle of Re is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-6 membered heterocyclyl, wherein the 3-6 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-6 membered heterocyclyl optionally substituted with one or more Ci-3alkyl, -OH, oxo or -S(O)2Ra, (vii) -S(O)-N(Ci-3alkyl)-(Ci-3alkyl), (viii) -CN, (ix) -(CH2)?OH, wherein q is an integer from 0-3, (x) -C(O)-Ci-3alkyl, or (xi) -P(O)(Ci-3alkyl)2; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-8 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-8 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(0)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-ecycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-3alkyl, or C3-6cycloalkyl, and wherein the C3-6cycloalkyl of the Ci-3alkyl of Rb is further optionally substituted with one or more Ci-3alkyl or -OH and the C3-6cycloalkyl of Rb is optionally substituted with one or more -OH, C3-6cycloalkyl, or Ci-3alkyl, and wherein the Ci-3alkyl of the C3-6cycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium, or halo, and the 5-10 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rc is optionally substituted with one or more -S(O)2-Ci-3alkyl, the C3-6cycloalkyl of Rc is optionally substituted with one or more -OH or Ci-3alkyl, and the 3-6 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-3alkyl, and wherein the Ci-3alkyl of the 3-6 membered heterocyclyl of Rc is further optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-3alkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-3alkyl, or -N(Ci-3alkyl)-C(O)-Ci-3alkyl, (ii) C3-6cycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-3alkyl, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, or -C(O)-C3-6heterocyclyl, or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH, (iii) 3-6 membered heterocyclyl optionally substituted with one or more Ci-3alkyl, or (iv) NH(Ci-3alkyl); R5 is, independently at each occurrence, H, halo, -CN, 3-6 membered heterocyclyl, Ci-3alkyl, or Ci-3alkoxy, wherein the Ci-3alkyl of R5 is optionally substituted with one or more halo or -OH, and the Ci-3alkoxy of R5 is optionally substituted with one or more halo; X3 is N or C(R6); X4 is N or C(R7); and R6 and R7 are each independently H or halo.

[0197] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 2; n is 1; p is an integer from 0; R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-3alkoxy, and Ci-3alkyl, wherein the Ci-3alkoxy of R1 is optionally substituted with one or more halo, and the Ci-3alkyl of R1 is optionally substituted with one or more halo; R2 is H, Ci-3alkyl, C3-6cycloalkyl, or 3-6 membered heterocyclyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more deuterium, halo, -OH, -NH2, or Ci-3alkoxy, and the C3-6cycloalkyl of R2 is optionally substituted with one or more -OH; L1 is Ci-3alkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more deuterium; L2 is O; and either (1) L3 is absent or is O, C3-ecycloalkyl, 3-6 membered heterocyclyl, or Ci-3alkylene, wherein the C3-6cycloalkyl of L3 is optionally substituted with one or more -OH or Ci-3alkyl, the Ci-3alkylene of L3 is optionally substituted with one or more -OH or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH, and the 3-6 membered heterocyclyl of L3 is optionally substituted with one or more -OH or Ci-3alkyl; X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra; (ii) 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl of R4 is optionally substituted with one or more Ci-3alkyl; (iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-3alkyl, or -S(O)2-Ra, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH, (iv) -NS(O)-(Ci-3alkyl)2, wherein the Ci-3alkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-3alkyl, or 3-6 membered heterocycle, wherein the 3-6 membered heterocycle of Re is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-6 membered heterocyclyl, wherein the 3-6 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, (vi) 3-6 membered heterocyclyl optionally substituted with one or more Ci-3alkyl, -OH, oxo or -S(O)2Ra , (ix) -(CH2)?OH, wherein q is an integer from 0-3; or (2) L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-8 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(0)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-3alkyl, or C3-6cycloalkyl, and wherein the C3-6cycloalkyl of the Ci-3alkyl of Rb is further optionally substituted with one or more Ci-3alkyl or -OH and the C3-6cycloalkyl of Rb is optionally substituted with one or more -OH, C3-6cycloalkyl, or Ci-3alkyl, and wherein the Ci-3alkyl of the C3-6cycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium, or halo, and the 5-10 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rc is optionally substituted with one or more -S(O)2-Ci-3alkyl, 133 the C3-6cycloalkyl of Rc is optionally substituted with one or more -OH or Cisalkyl, and the 3-6 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-3alkyl, and wherein the Ci-3alkyl of the 3-6 membered heterocyclyl of Rc is further optionally substituted with one or more -OH; Ra is, independently at each occurrence: (i) Ci-3alkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-3alkyl, or -N(Ci- 3alkyl)-C(O)-Ci-3alkyl, (ii) C3-6cycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-3alkyl, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, or -C(O)-C3-6heterocyclyl, or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH, (iii) 3-6 membered heterocyclyl optionally substituted with one or more Ci-3alkyl, or (iv) NH(Ci-3alkyl); R5 is, independently at each occurrence, H, halo, -CN, 3-6 membered heterocyclyl, Ci-3alkyl, or Ci-3alkoxy, wherein the Ci-3alkyl of R5 is optionally substituted with one or more halo or -OH, and the Ci-3alkoxy of R5 is optionally substituted with one or more halo; X3 is N or C(R6); X4 is N or C(R7); and R6 and R7 are each independently H or halo.

[0198] In some embodiments of a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 2; n is 1; p is an integer from 0; R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-3alkoxy, and Ci-3alkyl, wherein the Ci-3alkoxy of R1 is optionally substituted with one or more halo, and the Ci-3alkyl of R1 is optionally substituted with one or more halo; R2 is H; L1 is Ci-3alkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more deuterium; L2 is O; and either (1) L3 is absent or is Ci-3alkylene, wherein the Ci-3alkylene of L3 is optionally substituted with one or more -OH or Ci-3alkyl; X1 and X2 are each independently N or C(R5); and R4 is: (i)     -S(O)2-Ra; (ii)    -(CH2)?OH, wherein q is an integer from 0-3; or (2)    L3 is absent; and one of X1 and X2 is N or C(R5); and the other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-8 membered heterocyclyl or a 5-20 membered heteroaryl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence oxo, or C3-ecycloalkyl, wherein the C3-ecycloalkyl is optionally substituted with one or more -OH, C3-6cycloalkyl, or Ci-3alkyl, and the 5-10 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of Ci-3alkyl, C3-6cycloalkyl, wherein the C3-6cycloalkyl of Rc is optionally substituted with one or more -OH or Ci-3alkyl; Ra is, independently at each occurrence: (i) Ci-3alkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-3alkyl, or -N(Ci-3alkyl)-C(O)-Ci-3alkyl; R5 is, independently at each occurrence, H, halo, Ci-3alkyl, or Ci-3alkoxy, wherein the Ci-3alkyl of R5 is optionally substituted with one or more halo or -OH, and the Ci-3alkoxy of R5 is optionally substituted with one or more halo; X3 is N or C(R6); X4 is N or C(R7); and R6 and R7 are each independently H or halo.

[0199] In some embodiments, provided herein is a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of formula (I-A): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: n is 1 or 2; and m,p, R1, R2, R3, L1, L3, R4, X1, X2, R6, and R7 are as defined for formula (I). In some variations R1, R2, R3, L1, L3, R4, X1, X2, R6, and R7 of formula (I-A) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0200] In some embodiments, provided herein is a compound of formula (I) or formula (I-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of formula (I-Al): R2 (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m,p, R1, R2, R3, L1, L3, R4, X1, X2, R6, and R7 are as defined for formula (I). In some variations m,p, R1, R2, R3, L1, L3, R4, X1, X2, R6, and R7 of formula (I-Al) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0201] In some embodiments of a compound of formula (I), (I-A) or (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0202] In some embodiments of a compound of formula (I), (I-A) or (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 0. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0203] In some embodiments of a compound of formula (I), (I-A) or (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, / ? is an integer from 0 to 10. In some embodiments, / ? is 0 or 1. In some embodiments, / ? is 0. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0204] In some embodiments of a compound of formula (I), (I-A) or (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is Ci-ealkylene. In some embodiments, L1 is Ci-3alkylene. In some embodiments, L1 is ethylene. In some embodiments, ## L1 is # wherein, # denotes the point of attachment to -O- and ## denotes the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0205] In some embodiments of a compound of formula (I), (I-A) or (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0206] In some embodiments of a compound of formula (I), (I-A) or (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is methyl. In some embodiments, R4 is °' \ . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0207] In some embodiments of a compound of formula (I), (I-A) or (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, each of X1 and X2 is C(R5). In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0208] In some embodiments of a compound of formula (I), (I-A) or (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0209] In some embodiments of a compound of formula (I), (I-A) or (I-Al), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, each of R6 and R7 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0210] In some embodiments, provided herein is a compound of formula (I) or formula (I-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of formula (I-A2): R2 K (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, p, R1, R2, R3, L1, L3, R4, X1, X2, R6, and R7 are as defined for formula (I). In some variations, R1, R2, R3, L1, L3, R4, X1, X2, R6, and R7 of formula (I-A2) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0211] In some embodiments, provided herein is a compound of formula (I) or formula (I-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of formula (I-A3): R2 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: n is 1 or 2; and wherein m. n,p, R1, R2, R3, L1, X1, X2, R6, R7, and Ra are as defined for formula (I). In some variations, m, n,p, R1, R2, R3, L1, X1, X2, R6, R7, and Ra of formula (I-A3) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0212] In some embodiments, provided herein is a compound of formula (I), (I-A), or (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-B): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m,p, R1, R2, R3, L1, L3, R4, R5, R6, and R7 are as defined for formula (I). In some variations, m, p, R1, R2, R3, L1, L3, R4, R5, R6, and R7 of formula (I-B) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0213] In some embodiments, provided herein is a compound of formula (I), (I-A), (I-A2), or (IB), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-B 1): R2 ‘   ° R7 R6 R4 (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m. R1, R2, L1, L3, R4, R6, and R7 are as defined for formula (I). In some variations, m. R1, R2, L1, L3, R4, R6, and R7 of formula (I-B1) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0214] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0215] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl. In some embodiments, R2 is Ci-3alkyl. In some embodiments, R2 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0216] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl optionally substituted with one or more halo, -OH, or Ci-ealkoxy. In some embodiments, R2 is Ci-3alkyl optionally substituted with one or more halo, -OH, or Ci-3alkoxy. In some embodiments, R2 is ethyl optionally substituted with one or more halo, -OH, NH2, or Ci-3alkoxy. In some embodiments, R2 is selected from the group consisting of F OH In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0217] In some embodiments of a compound of formula (II), such as a compound of formula (I- A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl optionally substituted with one or more deuterium, halo, -OH, or Ci-ealkoxy. In some embodiments, R2 is Ci-3alkyl optionally substituted with one or more deuterium, halo, -OH, or Ci-3alkoxy. In some embodiments, R2 is methyl optionally substituted with one or more deuterium halo, -OH, NH2, or Ci-3alkoxy. In some embodiments, R2 is ethyl optionally substituted with one or more deuterium halo, -OH, NH2, or Ci-3alkoxy. In some embodiments, R2 is selected from the group consisting of D D

[0218] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is C3-iocycloalkyl optionally substituted with one or more -OH. In some embodiments, R2 is C3-6 OH cycloalkyl optionally substituted with one or more -OH. In some embodiments, R2 is^ . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0219] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is 3-15 membered heterocyclyl. In some embodiments, R2 is 3-6 membered heterocyclyl. In some embodiments, R2 is H N In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0220] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 0. In some embodiments m is 1. In some embodiments, m is 2. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0221] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo. In some embodiments R1 is Cl. In some embodiments, R1 is Br. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0222] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is Ci-ealkyl. In some embodiments, R1 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0223] In some embodiments of a compound of formula (I’), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is Ci-ealkyl, wherein the Ci-ealkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is Ci-3alkyl, wherein the Ci-3alkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is methyl, wherein the methyl of R1 is optionally substituted with one or more F. In some embodiemtns. R1 is In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0224] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0225] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, / ? is an integer from 0 to 10. In some embodiments, / ? is 0. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0226] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is Ci-ealkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more Ci-ealkyl. In some embodiments, L1 is Ci-3alkylene optionally substituted with one or more Ci-3alkyl. In some embodiments, L1 is ethylene optionally substituted with one or more Ci-ealkyl. In some embodiments, L1 is selected from the group consisting of #,       #, and          wherein, for each L1, # denotes the point of attachment to -O- and ## denotes the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0227] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0228] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene. In some embodiments, L3 Ci-3alkylene. In some embodiments, L3 is selected from the group consisting of In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0229] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is C3-iocycloalkyl, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is C3-scycloalkyl, wherein the C3-scycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is selected from the group consisting of , OH , and              . In some variations, the embodiments provided herein also apply to a compound of formula (I’) or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0230] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl. In some embodiments, L3 is 3-6 membered heterocyclyl. In some embodiments, L3 is selected from the group consisting of In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0231] In some embodiments of a compound of formula (II), such as a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl. In some embodiments, L3 is 3-6 membered heterocyclyl. In some embodiments, L3 is selected from the group consisting of

[0232] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl, wherein the Ci-ealkyl of Ra is optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-3alkyl, wherein the Ci-3alkyl of Ra is optionally substituted with one or more halo, -OH, -S(O)2-Ci-3alkyl, or -N(Ci-3alkyl)-C(O)-Ci-3alkyl. In some embodiments, R4 is selected from the group consisting of embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0233] In some embodiments of a compound of formula (II), such as a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically

[0234] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is C3-iocycloalkyl. R4 is -S(O)2-Ra, wherein Ra is C3-iocycloalkyl, wherein the C3-iocycloalkyl of Ra is optionally substituted with one or more -OH, C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(0)-N(Ci-6alkyl)2,-C(0)-C3-ioheterocyclyl or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is C3-ecycloalkyl, wherein the C3-6cycloalkyl of Ra is optionally substituted with one or more -OH, C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is C3-6cycloalkyl, wherein the C3-6cycloalkyl of Ra is optionally substituted with one or more -OH, C(O)2-Ci-3alkyl, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -C(O)-C3-6heterocyclyl, or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH. In some to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0235] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is 3-10 membered heterocyclyl. In some embodiments R4 is -S(O)2-Ra, wherein Ra is 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl of Ra is optionally substituted with one or more Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is 3-6 membered heterocyclyl, wherein the 3-6 membered heterocyclyl of Ra is optionally substituted with one or more Ci-ealkyl. In some embodiments, wherein R4 is -S(O)2-Ra, wherein Ra is 3-6 membered heterocyclyl, wherein the 3-6 membered heterocyclyl of Ra is optionally X" o substituted with one or more Ci-3alkyl. In some embodiments, R4 is °       . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0236] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is 5-20 membered heteroaryl. In some embodiments, R4 is 5-20 membered heteroaryl optionally substituted with one or more Ci-ealkyl. In some embodiments, R4 is 5-6 membered heteroaryl optionally substituted with one or more Ci-ealkyl. In some embodiments, R4 is 5-6 membered heteroaryl optionally substituted with one or more Ci-3alkyl. In some embodiments, R4 is 5-6 membered heteroaryl optionally substituted with one or more methyl. In some embodiments, R4 is lx selected from the group consisting of N , N , and °     . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0237] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -N(Rd)2, wherein each of Rd is independently H, or Ci-6 alkyl, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH or -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is independently H, or C1-3 alkyl, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH, or -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is independently H, or Ci-3alkyl, wherein the Ci-3alkyl of Rd is optionally substituted with one or more -OH or -S(O)2-Ra, wherein Ra is methyl. O^H o^- In some embodiments, R4 is selected from the group consisting of-NH2,                , and Oj ^OH \         . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0238] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or Ci-6 alkyl. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or C1-3 alkyl. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or methyl. In some embodiments, R4 is -C(O)-NH2. In some embodiments, R4 is -C(O)-NH(CH3). In some embodiments, R4 is -C(O)-N(CH3)2. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0239] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl. In some embodiments R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, NH-S(O)2-Ra, or -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-7 membered heterocyclyl, wherein the 3-7 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, NH-S(O)2-Ra, or -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-7 membered heterocyclyl, wherein the 3-7 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, NH-S(O)2-Ra, or -S(O)2-Ra, wherein Ra is methyl. In some embodiments, R4 is selected from the group consisting of > / ° , and '         . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0240] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is 3-10 membered heterocyclyl optionally substituted with one or more oxo. In some embodiments, R4 is 3-7 membered heterocyclyl optionally substituted with one or more oxo. In some embodiments, X O   X O W VXo R4 is selected from the group consisting of          , and . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0241] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -NS(O)-(Ci-6alkyl)2.In some embodiments, R4 is -NS(O)-(Ci-3alkyl)2. In some embodiments, wherein R4 is ।   . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0242] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)-N(Ci-6alkyl)-(Ci-6alkyl). In some embodiments, R4 is -S(O)-N(Ci-3alkyl)-(Ci-3alkyl). In some \ embodiments, R4 is ।      . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0243] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0244] In some embodiments of a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -P(O)(Ci-6alkyl)2. In some embodiments, R4 is -P(O)(Ci-3alkyl)2. In some embodiments, R4 is -P(O)(CH3)2. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0245] In some embodiments, provided herein is a compound of formula (I), (I-A), (I-A2), or (IB), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-B2): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R5 is halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy is optionally substituted with one or more halo; and m, R1, R2, L1, L3, R4, R6, and R7 are as defined for formula (I). In some variations, m. R1, R2, L1, L3, R4, R6, and R7 of formula (I-B2) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0246] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0247] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more halo, -OH. In some embodiments, R2 is Ci-3alkyl, wherein the Ci-3alkyl of R2 is optionally substituted with one or more halo, -OH. In some embodiments, R2 is methyl. In some embodiments, R2 is ethyl, wherein the ethyl OH of R2 is optionally substituted with one or more halo, -OH. In some embodiments, R2 is         . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0248] In some embodiments of a compound of formula (II), such as a compounf of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more deuterium. In some embodiments, R2 is Ci-3alkyl, wherein the Ci-3alkyl of R2 is optionally substituted with one or more deuterium. In some embodiments, R2 is methyl, wherein the methyl of R2 is optionally substituted with one of more deuterium. In some D D V-D embodiments, R2 is .

[0249] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0250] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo. In some embodiments R1 is Cl. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0251] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0252] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is Ci-ealkylene optionally substituted with one or more Ci-6alkyl, wherein the Ci-ealkyl is optionally substituted with -OH or Ci-ealkoxy. In some embodiments, L1 is methylene. In some embodiments, L1 is ethylene optionally substituted with one or more Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH or Ci-ealkoxy. In some embodiments, L1 is selected from the group consisting of #,       #, and          wherein, for each L1, # denotes the point of attachment to -O- and ## denotes the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0253] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0254] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl. In some embodiments, L3 is 3-6 membered heterocyclyl. In some / 0° embodiments, L3 is         . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0255] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, R4 is \ . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0256] In some embodiments of a compound of formula (II) such as a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4is -NS(O)-(Ci-6alkyl)2. In some embodiments, R4 is -NS(O)-(Ci-ealkyl)2. In some embodiments, R4 is -NS(O)-(Ci-3alkyl)2. In some embodiments, R4 is

[0257] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -N(Rd)2, wherein each of Rd is independently H, Ci-6 alkyl, or -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is independently H, C1-3 alkyl, or -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is independently H, Ci-6 alkyl, or -S(O)2-Ra, wherein Ra is methyl. In some embodiments, R4 is selected from the > group consisting of -NH2, and . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0258] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or Ci-6 alkyl. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or C1-3 alkyl. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or methyl. In some embodiments, R4 is -C(O)-NH2. In some embodiments, R4 is -C(O)-NH(CH3). In some embodiments, R4 is -C(O)-N(CH3)2. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0259] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or 3-10 membered heterocycle, wherein the 310 membered heterocycle is optionally substituted with one or more oxo. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or 3-6 membered heterocycle, wherein the 3-6 membered heterocycle is optionally substituted with one or more oxo. In some embodiments, R4 H^0 Q is selected from the group consisting of 0 , and 0 . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0260] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl. In some embodiments R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more oxo, -OH, NH2, or -S(0)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-7 membered heterocyclyl, wherein the 3-7 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, NH-S(0)2-Ra, or -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments R4 is -C(0)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-7 membered heterocyclyl, wherein the 3-7 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, NH-S(0)2-Ra, or -S(O)2-Ra, wherein some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0261] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is halo. In some embodiments, R5 is Cl, or F. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0262] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0263] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is Ci-ealkyl, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH. In some embodiments, R5 is Ci-3alkyl, wherein the Ci-3alkyl of R5 is optionally substituted with one or more halo, or -OH. In some embodiments, R5 is Ci-3alkyl, wherein the Ci-3alkyl of R5 is optionally substituted with one or more fluoro, or -OH. In some embodiments, R5 is selected from the group >         '5-a consisting of methyl, , F F , F                      . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0264] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is 3-10 membered heterocyclyl. In some embodiments, R5 is 3-6 membered heterocyclyl. In some embodiments, R5 is In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0265] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is Ci-ealkoxy, wherein the Ci-ealkoxy is optionally substituted with one or more halo. In some embodiments R5 is Ci-3alkoxy, wherein the Ci-3alkoxy is optionally substituted with one or more halo. In some embodiments, R5 is Ci-3alkoxy, wherein the Ci-3alkoxy is optionally substituted with F—( one or more fluoro. In some embodiments, R5 is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0266] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R6 and R7 are each independently H or halo. In some embodiments, R6 and R7 are each independently H or fluoro. In some embodiments, each of R6 and R7 is H. In some embodiments, one of R6 and R7 is H and the other of R6 and R7 is fluoro. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0267] In some embodiments, provided herein is a compound of formula (I), (I-A), (I-A2), or (IB), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-B3): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: each R5 is, independently at each occurrence, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy is optionally substituted with one or more halo; and m, R1, R2, L1, L3, R4, R6, and R7 are as defined for formula (I). In some variations, m, R1, R2, L1, L3, R4, R6, and R7 of formula (I-B3) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0268] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0269] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl. In some embodiments, R2 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0270] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is 0 or 1. In some embodiments, m is 0. In some embodiments m is 1. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0271] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo. In some embodiments R1 is Cl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0272] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0273] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is Ci-ealkylene optionally substituted with one or more Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with -OH or Ci-ealkoxy. In some embodiments, L1 is methylene. In some embodiments, L1 is ethylene optionally substituted with one or more Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH or Ci-ealkoxy. In some embodiments, L1 is selected from the group consisting of #,       #, and          wherein, for each L1, # denotes the point of attachment to -O- and ## denotes the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0274] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0275] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene. In some embodiments, L3 is Ci-3alkylene. In some embodiments, L3 is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0276] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl. In some embodiments, L3 is 3-6 membered heterocyclyl. In some embodiments, L3 is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0277] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, R4 is \ . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0278] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -N(Rd)2, wherein each of Rd is independently Ci-6 alkyl, or -S(O)2-Ra, and wherein Ra is Ci-ealkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is independently C1-3 alkyl, or -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, R4 is -N(Rd)2, wherein each of Rd is methyl, or - 4- S(O)2-Ra, wherein Ra is methyl. In some embodiments, R4 is ° ' . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0279] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more oxo. In some embodiments R4 is -C(O)-N(Re)2, wherein both Re together with the N to which they are attached are taken together to form a 3-7 membered heterocyclyl, wherein the 3-7 membered heterocyclyl is optionally substituted with one or more oxo. 4 In some embodiments, R is 0     . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0280] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-B), or (I-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is, independently at each occurrence selected from the group consisting of, halo and Ci-ealkyl. In some embodiments, R5 is, independently at each occurrence selected from the group consisting of halo and Ci-3alkyl. In some embodiments, R5 is, independently at each occurrence, selected from the group consisting of F and methyl. In some embodiments, each R5 is F. In some embodiments, each R5 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0281] In some embodiments, provided herein is a compound of formula (I), (I-A), or (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-C): R2 (R1)™—[k _T)=O (rVW R5 L3 r / (I-C),

[0282] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m,p, R1, R2, R3, L1, L3, R4, and R5 are as defined for formula (I). In some variations m, p, R1, R2, R3, L1, L3, R4, and R5 of formula (I-C) are as defined for a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0283] In some embodiments, provided herein is a compound of formula (I), (I-A), (I-A2), or (IC), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-Cl):

[0284] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m. R1, R2, R3, L1, L3, and R4, are as defined for formula (I). In some variations m, R1, R2, R3, L1, L3, and R4 of formula (I-C) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0285] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0286] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments m is 1. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0287] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo. In some embodiments R1 is Cl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0288] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0289] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is ## Ci-ealkylene. In some embodiments, L1 is ethylene. In some embodiments, L1 is # wherein, # denotes the point of attachment to -O- and ## denotes the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0290] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-Cl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0291] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene. In some embodiments, L3 is Ci-3alkylene. In some embodiments, L3 is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0292] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, R4 is \ . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0293] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is C3-iocycloalkyl. R4 is -S(O)2-Ra, wherein Ra is C3-iocycloalkyl, wherein the C3-iocycloalkyl of Ra is optionally substituted with one or more Ci-ealkyl, and wherein the Ci-ealkyl is optionally substituted with one or more -OH. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is C3-6cycloalkyl, wherein the C3-6cycloalkyl of Ra is optionally substituted with one or more Ci-ealkyl, and wherein the Ci-ealkyl is optionally substituted with one or more -OH. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is C3-6cycloalkyl, wherein the C3-6cycloalkyl of Ra is optionally substituted with one or more Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted X O with one or more -OH. In some embodiments, R4 is HO . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0294] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-Cl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is 3-10 membered heterocyclyl. In some embodiments R4 is -S(O)2-Ra, wherein Ra is 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl of Ra is optionally substituted with one or more Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is 3-6 membered heterocyclyl, wherein the 3-6 membered heterocyclyl of Ra is optionally substituted with one or more Ci-ealkyl. In some embodiments, wherein R4 is -S(O)2-Ra, wherein Ra is 3-6 membered heterocyclyl, wherein the 3-6 membered heterocyclyl of Ra is optionally X^p \X*o substituted with one or more Ci-3alkyl. In some embodiments, R4 is °      . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0295] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or Ci-6 alkyl. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or C1-3 alkyl. In some embodiments, R4 is -C(O)-N(Re)2, wherein each of Re is independently H or methyl. In some embodiments, R4 is -C(O)-165 NH2. In some embodiments, R4 is -C(O)-N(CH3)2. In some embodiments, R4 is -C(O)-NH2. In some embodiments, R4 is -C(O)-NH(CH3). In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0296] In some embodiments, provided herein is a compound of formula (I), (I-A), or (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-C2): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: R5 is, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy is optionally substituted with one or more halo; R1, R2, R3, L1, L3, and R4, are as defined for formula (I). In some variations, R5 is halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy of R5 is optionally substituted with one or more halo; R1, R2, R3, L1, L3, and R4 of formula (I-C2) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0297] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0298] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments m is 1. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0299] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo. In some embodiments R1 is Cl. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0300] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0301] In some embodiments of a compound of formula (I’), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is Ci-ealkyl, wherein the Ci-ealkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is Ci-3alkyl, wherein the Ci-3alkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is methyl, wherein the methyl of R1 is optionally substituted with \ F one or more F. In some embodiemtns. R1 is . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0302] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is ## Ci-ealkylene. In some embodiments, L1 is ethylene. In some embodiments, L1 is #, wherein, # denotes the point of attachment to -O- and ## denotes the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0303] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0304] In some embodiments of a compound formula (F), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl. In some embodiments, L3 is Ci-3alkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl. In some embodiments, L3 is selected from the group In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0305] In some embodiments of a compound formula (II), such as a compound of formula (I’), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH. In some embodiments, L3 is Ci-3alkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with one or more -OH. In some embodiments, L3 is selected from the group

[0306] In some embodiments of a compound of formula (I’), (I), (I-A), (I-A2), (I-B), or (I-Bl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is C3-iocycloalkyl, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is C3-scycloalkyl, wherein the C3-scycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0307] In some embodiments of a compound formula (II), such as a compound of formula (I’), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl, optionally substituted with one or more -OH or Ci-ealkyl. In some embodiments, L3 is 3-6 membered heterocyclyl, L optionally substituted with one or more -OH or Ci-3alkyl. In some embodiments, L3 is

[0308] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, R4 is \ . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0309] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -(CH2)?OH, wherein q is an integer from 0-6. R4 is -(CH2)?OH, wherein q is an integer from 0-2. In some embodiments, R4 is -OH. In some embodiments, R4 is selected from the group consisting of , and^^H . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0310] In some embodiments of a compound of formula (I’), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-Ci-6alkyl. In some embodiments, R4 is -C(O)-Ci-3alkyl. In some embodiments, R4 is -C(O)CH3. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0311] In some embodiments of a compound of formula (I), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is Ci-ealkyl. In some embodiments, R5 is Ci-3alkyl. In some embodiments, R5 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0312] In some embodiments of a compound of formula (I’), (I-A), (I-A2), (I-C), or (I-C2) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is Ci-6alkyl, wherein the Ci-6alkyl of R5 is optionally substituted with one or more halo. In some embodiments, R5 is Ci-3alkyl, wherein the Ci-3alkyl of R5 is optionally substituted with one or more halo. In some embodiments, R5 is Ci-3alkyl, wherein the Ci-3alkyl of R5 is optionally substituted with one or more fluoro. In some embodiments, R5 is F F . In some embodiments, R5 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0313] In some embodiments of a compound of formula (I’), (I-A), (I-A2), (I-C), or (I-C2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R5 is halo. In some embodiments, R5 is Cl, or F. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0314] In some embodiments, provided herein is a compound of formula (I), (I-A), or (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-D): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: m,p, R1, R2, R3, L1, L3, and R4, are as defined for formula (I). In some variations, m,p, R1, R2, R3, L1, L3, and R4 of formula (I-D) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0315] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0316] In some embodiments of a compound of formula (II), such as a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl optionally substituted with one or more deuterium. In some embodiments, R2 is Ci-3alkyl optionally substituted with one or more deuterium. In some embodiments, R2 is methyl optionally substituted with one or more deuterium. In some D D Y-D embodiments, R2 is .

[0317] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments m is 1. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0318] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo. In some embodiments R1 is Cl. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0319] In some embodiments of a compound of formula (II), such as a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is Cl, or I.

[0320] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0321] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is Ci-ealkyl, wherein the Ci-ealkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is Ci-3alkyl, wherein the Ci-3alkyl of R1 is optionally substituted with one or more halo. In some embodiments, R1 is Ci-3alkyl, wherein the Ci-3alkyl of R1 is optionally substituted with one or more F. In some embodiments, R1 is methyl, wherein the methyl of R1 is optionally F \,F substituted with one or more F. In some embodiments, R1 is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0322] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is Ci-ealkylene optionally substituted with one or more Ci-ealkyl. In some embodiments, L1 is ethylene optionally substituted with one or more Ci-ealkyl. In some embodiments, L1 is selected from the 172 ## group consisting of # wherein, for each L1, # denotes the point of attachment to -O- and ## denotes the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0323] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is absent. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0324] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is -O-. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0325] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene. In some embodiments, L3 is Ci-3alkylene. In some embodiments, L3 is . In some variations, the embodiments provided herein also apply to a compound of formula (I’) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0326] In some embodiments of a compound of formula (I’), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is Ci-ealkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl. In some embodiments, L3 is Ci-3alkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl. In some embodiments, L3 is selected from the group

[0327] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is C3-iocycloalkyl. In some embodiments, L3 is C3-8cycloalkyl. In some embodiments, L3 is . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0328] In some embodiments of a compound of formula (I’), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is C3-iocycloalkyl, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is C3-scycloalkyl, wherein the C3-scycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is selected from the group consisting of , and In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0329] In some embodiments of a compound of formula (II), such as a compound of formula (I’), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is C3-iocycloalkyl, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is C3-8cycloalkyl, wherein the C3-8-cycloalkyl of L3 is optionally substituted with one or more -OH. In some embodiments, L3 is selected from the group consisting of ,         , and

[0330] In some embodiments of a compound of formula (I’), (I-A), (I-A2), or (I-D) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl. In some embodiments, L3 is 3-6 membered heterocyclyl. In some . A / 0°      \ embodiments, L3 is selected from the group consisting of , and . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0331] In some embodiments of a compound of formula (II), such as a compound of (F), (I-A), (I-A2), or (I-D) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L3 is 3-10 membered heterocyclyl. In some embodiments, L3 is 3-6 membered A / 0° \ heterocyclyl. In some embodiments, L3 is selected from the group consisting of ,

[0332] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -S(O)2-Ra, wherein Ra is Ci-ealkyl. In some embodiments, R4 is -S(O)2-Ra, wherein Ra is Ci-3alkyl. In some embodiments, R4 is °     . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0333] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -C(O)-N(Re)2, wherein each of Re is H. In some embodiments, R4 is -C(O)-NH2. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0334] In some embodiments of a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is 3-10 membered heterocyclyl optionally substituted with one or more Ci-6 alkyl. In some embodiments, R4 is 3-6 membered heterocyclyl optionally substituted with one or more Ci-6 alkyl. In some embodiments, R4 is 3-6 membered heterocyclyl optionally substituted with one or more C1-3 alkyl. In some embodiments, R4 is 3-6 membered heterocyclyl optionally substituted with one or A more methyl. In some embodiments, R4 is 0 . In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0335] In some embodiments of a compound of formula (II), such as a compound of formula (I), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt % of any of the foregoing, R4 is , or / x .

[0336] In some embodiments of a compound of formula (I’), (I-A), (I-A2), or (I-D), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is 3-10 membered heterocyclyl optionally substituted with one or more Ci-6 alkyl. In some embodiments, R4 is 3-6 membered heterocyclyl optionally substituted with one or more Ci-6 alkyl. In some embodiments, R4 is 3-6 membered heterocyclyl optionally substituted with one or more C1-3 alkyl. In some embodiments, R4 is 3-6 membered heterocyclyl optionally substituted with one or A more methyl. In some embodiments, R4 is selected from the group consisting of        , and O . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0337] In some embodiments of a compound of formula (I’), (I-A), (I-A2), or (I-D) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -(CH2)?OH, wherein q is an integer from 0-6. R4 is -(CH2)?OH, wherein q is an integer from 0-2. In some embodiments, R4 is -OH. In some embodiments, R4 is selected from the group consisting of H^, and^^n. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0338] In some embodiments of a compound of formula (I’), (I-A), (I-A2), or (I-D) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -N(Rd)2, wherein each of Rd is independently H. In some embodiments, R4 is -NH2. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0339] In some embodiments of a compound of formula (I’), (I-A), (I-A2), or (I-D) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4 is -P(O)(Ci-ealkyl)2. In some embodiments, R4 is -P(O)(Ci-3alkyl)2. In some embodiments, R4 is -P(O)(CH3)2. In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0340] In some embodiments, provided herein is a compound of formula (I), (I-A) or (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-E): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: ring A is 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl of ring A is optionally substituted with one or more Rb, and wherein the 510 membered heteroaryl of ring A is optionally substituted with one or more Rc; and m,p, R1, R2, R3 L1, X2, Rb, Rc, R6, and R7 are as defined for formula (I). In some variations, ring A is 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl of ring A is optionally substituted with one or more Rb, and wherein the 5-10 membered heteroaryl of ring A is optionally substituted with one or more Rc; and m,p, R1, R2, R3 L1, X2, Rb, Rc, R6, and R7 of formula (I-E) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0341] In some embodiments, provided herein is a compound of formula (I), (I-A) or (I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-E 1): R2 (LEI), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: ring A is 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl of ring A is optionally substituted with one or more Rb, and wherein the 510 membered heteroaryl of ring A is optionally substituted with one or more Rc; and R1, R2, R3, L1, X1, Rb, Rc, R6, and R7 are as defined for formula (I). In some variations, ring A is 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl of ring A is optionally substituted with one or more Rb, and wherein the 5-10 membered heteroaryl of ring A is optionally substituted with one or more Rc; and m,p, R1, R2, R3, L1, X1, Rb, Rc, R6, and R7 of formula (I-El) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0342] In some embodiments, provided herein is a compound of formula (I’), (I-A), (I-A2), or (I-E) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-E2): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: r is an integer from 0-1; Y1 and Y2 are each independently C or N, optionally substituted by one or more H or Rb; and m. R1, R2, L1, X2, and Rb are as defined for formula (I’), or (II); and wherein the dashed line represents a single or double bond.

[0343] In some embodiments, provided herein is a compound of formula (I’), (I-A), (I-A2), or (I-E) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-E3): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: r is an integer from 0-1; Y1 and Y2 are each independently C or N, optionally substituted by one or more H or Rb; Rbl is OH; Rb2 is H, Ci-ealkyl, or C3-iocycloalkyl, wherein the Ci-ealkyl of Rb2 is optionally substituted with one or more OH; and m, R1, R2, L1, X2, and Rb are as defined for formula (I’), or (II); and wherein the dashed line represents a single or double bond.

[0344] In some embodiments of a compound of formula (I’), (I-A) (I-A2), or (I-E3) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0345] In some embodiments of a compound of formula (I’), (I-A) (I-A2), or (I-E3) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the moiety represented by Rb1 o rM i—Rb2 , has a stereochemical configuration represented by . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0346] In some embodiments, provided herein is a compound of formula (I’), (I-A), (I-A2), or (I-E) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-E4): R2 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: r is an integer from 0-1; Y2, Y3 and Y4 are each independently C or N, optionally substituted by one or more H or Rc; and m, R1, R2, L1, X2, and Rc are as defined for formula (I’), or (II); and wherein the dashed line represents a single or double bond.

[0348] In some embodiments, provided herein is a compound of formula (I’), (I-A), (I-A2), or (I-E) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-E5): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: r is an integer from 0-1; Y3, Y4 and Y5 are each independently C or N, optionally substituted by one or more H or Rc; RC1 is OH; Rc2 is H, Ci-ealkyl, or C3-iocycloalkyl, wherein the Ci-ealkyl of Rc2 is optionally substituted with one or more OH; and m, R1, R2, L1, X2, and Rc are as defined for formula (I’), or (II); and wherein the dashed line represents a single or double bond.

[0349] In some embodiments of a compound of formula (I’), (I-A) (I-A2), or (I-E5) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the , has a stereochemical configuration represented by moiety represented by In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0350] In some embodiments of a compound of formula (I’), (I-A) (I-A2), or (I-E) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the Rc1 \ y5 moiety represented by                        , has a stereochemical configuration represented by Rc1 . In some variations, the embodiments provided herein also apply to a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0351] In some embodiments, provided herein is a compound of formula (I), (I-A) or (I-A2), (IE), or (I-El), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-F): R2 f A । (I-F), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: ring A is 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl of ring A is optionally substituted with one or more Rb, and wherein the 510 membered heteroaryl of ring A is optionally substituted with one or more Rc; and m,p, R1, R2, R3, L1, R5, Rb, and Rc, are as defined for formula (I). In some variations, ring A is 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl of ring A is optionally substituted with one or more Rb, and wherein the 5-10 membered heteroaryl of ring A is optionally substituted with one or more Rc; and m,p, R1, R2, R3, L1, R5, Rb, and Rc of formula (I-F) are as defined for a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0352] In some embodiments, provided herein is a compound of formula (I), (I-A) or (I-A2), (IE), (I-El), or (I-F), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (I-Fl): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: ring A is 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl of ring A is optionally substituted with one or more Rb, and wherein the 510 membered heteroaryl of ring A is optionally substituted with one or more Rc; and m. R1, R2, L1, Rb, and Rc, are as defined for formula (I). In some variations, ring A is 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl of ring A is optionally substituted with one or more Rb, and wherein the 5-10 membered heteroaryl of ring A is optionally substituted with one or more Rc; and m, R1, R2, L1, Rb, and Rc of formula (I-Fl) are as defined for a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0353] In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is H. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0354] In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more -OH, -NH2, or Ci-ealkoxy. In some embodiments, R2 is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0355] In some embodiments of a compound of formula (II), such as a compound of formula (I’), (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is Ci-ealkyl, wherein the Ci-ealkyl of R2 is optionally substituted with one or more deuterium, -OH, -NH2, or Ci-ealkoxy. In some embodiments, R2 is methyl optionally substituted with one or more deuterium. In some D D v_d embodiments, R2 is .

[0356] In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2 is C3-iocycloalkyl, wherein the C3-iocycloalkyl of R2 is optionally substituted with one or more -OH. In some embodiments, R2 is C3-6cycloalkyl, wherein the C3-6cycloalkyl of R2 is OH optionally substituted with one or more -OH. In some embodiments, R2 is . In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0357] In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is an integer from 0 to 4. In some embodiments, m is an integer from 0 to 2. In some embodiments, m is 0 or 1. In some embodiments, m is 0. In some embodiments m is 1. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0358] In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is halo. In some embodiments R1 is Cl. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0359] In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1 is -CN. In some variations, the embodiments provided herein also apply to a compound of formula (F) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L1 is Ci-ealkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more Ci-6alkyl. In some embodiments, L1 is ethylene, wherein the ethylene of L1 is optionally substituted with one or more ##\__ ##\__ Ci-ealkyl. In some embodiments, L1 is selected from the group consisting of #,       #, and ## Xa,             . *, wherein, for each L1, # denotes the point of attachment to -O- and ## denotes the point of attachment to the remainder of the molecule. In some variations, the embodiments provided herein also apply to a compound of formula (F), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0360] In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, ring A is a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more of Rb, wherein Rb is oxo. In some embodiments, ring A is a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more of Rb, wherein Rb is oxo. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0361] In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-E), (I-El), (I-F), or (I-Fl), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the attachment to the remainder of the molecule and the dashed line represents a single or double bond. In some variations, the embodiments provided herein also apply to a compound of formula (I’), or (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0362] In some embodiments of a compound of formula (I), (I-A) or (I-A2), (I-El), (I-E2), (IF), or (I-F 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, ring A is a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein each Rb is independently oxo, or Ci-ealkyl. In some embodiments, ring A is a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein each Rb is independently oxo, or Ci-ealkyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more more halo, OH , or -S(O)2-Ci-ealkyl. In some embodiments, ring A is a 5-10 membered heterocyclyl, wherein the 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein wherein each Rb is independently oxo, or Ci-3alkyl, wherein the Ci-3alkyl of Rbis optionally subst...

Claims

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:m is an integer from 0 to 4;n is an integer from 0 to 2;p is an integer from 0 to 10;R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-ealkoxy, and Ci-ealkyl, whereinthe Ci-ealkoxy of R1 is optionally substituted with one or more halo, andthe Ci-ealkyl of R1 is optionally substituted with one or more halo;R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, whereinthe Ci-ealkyl of R2 is optionally substituted with one or more deuterium, halo, -OH, -NH2, or Ci-ealkoxy, andthe C3-iocycloalkyl of R2 is optionally substituted with one or more -OH;R3, if present, is Ci-ealkyl;L1 is Ci-ealkylene, whereinthe Ci-ealkylene of L1 is optionally substituted with one or more deuterium or Ci-ealkyl, and whereinthe Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy;L2 is O or N(RX), wherein Rx is H or Ci-ealkyl; andeither(1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl, the Ci-ealkylene of L3 is optionally substituted with one or more -OH or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, andthe 3-10 membered heterocyclyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl;X1 and X2 are each independently N or C(R5); andR4 is:(i)     -S(O)2-Ra;(ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl;(iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH,(iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-6 alkyl, or 3-10membered heterocycle, whereinthe 3-10 membered heterocycle of Re is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, whereinthe 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra,(vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH , oxo or -S(O)2Ra,(vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl),(viii) -CN,(ix) -(CH2)?OH, wherein q is an integer from 0-6,(x) -C(O)-Ci-ealkyl, or(xi) -P(O)(Ci-6alkyl)2;or(2) L3 is absent; andone of X1 and X2 is N or C(R5); andthe other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, whereinthe 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-6alkyl, -C(O)-Ci-6alkyl, -C(0)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, and whereinthe C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH andthe C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, C3-iocycloalkyl, or Ci-ealkyl, and whereinthe Ci-ealkyl of the C3-iocycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium, or halo, andthe 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, andthe 3-10 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and whereinthe Ci-ealkyl of the 3-10 membered heterocyclyl of Rc is further optionally substituted with one or more -OH;Ra is, independently at each occurrence:(i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-ealkyl,(ii) C3-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, whereinthe Ci-ealkyl is optionally substituted with one or more -OH,(iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, or(iv) NH(Ci-ealkyl);R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, whereinthe Ci-ealkyl of R5 is optionally substituted with one or more halo or -OH, andthe Ci-ealkoxy of R5 is optionally substituted with one or more halo;X3 is N or C(R6);X4 is N or C(R7);andR6 and R7 are each independently H or halo.

2. The compound of claim 1, wherein the compound is a compound of formula (I’):or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:m is an integer from 0 to 4;n is an integer from 0 to 2;p is an integer from 0 to 10;R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-ealkoxy, or Ci-ealkyl, whereinthe Ci-ealkoxy of R1 is optionally substituted with one or more halo, andthe Ci-ealkyl of R1 is optionally substituted with one or more halo;R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, whereinthe Ci-ealkyl of R2 is optionally substituted with one or more halo, -OH, -NH2, or Ci-ealkoxy, andthe C3-iocycloalkyl of R2 is optionally substituted with one or more -OH;R3, if present, is Ci-ealkyl;L1 is Ci-ealkylene, wherein the Ci-ealkylene of L1 is optionally substituted with one or more Ci-ealkyl, and wherein the Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy;L2 is O or N(RX), wherein Rx is H or Ci-ealkyl; andeither(1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl is optionally substituted with one or more -OH, or Ci-ealkyl, the Ci-ealkylene of L3 is optionally substituted with one or more -OH, or Ci-ealkyl, andthe 3-10 membered heterocyclyl is optionally substituted with one or more -OH;X1 and X2 are each independently N or C(R5); andR4 is:(i)     -S(O)2-Ra;(ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl;(iii) -N(Rd)2, wherein Rd is independently at each occurrence H, C1-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH,(iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl is optionally substituted with one or more -OH,(v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, C1-6 alkyl, or3-10 membered heterocycle, wherein the 3-10 membered heterocycle is optionally1067substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra,(vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH , oxo or -S(O)2Ra ,(vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl),(viii) -CN,(ix) -(CH2)?OH, wherein q is an integer from 0-6,(x) -C(O)-Ci-ealkyl, or(xi) -P(O)(Ci-6alkyl)2;or(2) L3 is absent; andone of X1 and X2 is N or C(R5); andthe other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, whereinthe 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of halo, oxo, Ci-6alkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, andwherein the C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH andthe C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, C3-wcycloalkyl, or Ci-ealkyl, andwherein the Ci-ealkyl of the C3-iocycloalkyl of Rb is further optionally substituted with one or more -OH, andthe 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, 1068-C(0)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci.6alkyl)2, -S(O)2-Ra, C3-locycloalkyl, and 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl,the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH, or Ci-ealkyl,and the 3-10 membered heterocyclyl of Rc is optionally substituted with one or more -OH, or Ci-ealkyl, andwherein the Ci-ealkyl of 3-10 membered heterocyclyl of Rc is further optionally substituted with one or more -OH;Ra is, independently at each occurrence:(i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl,(ii) C3-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, or(iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl;R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy of R5 is optionally substituted with one or more halo; andR6 and R7 are each independently H or halo.

3. The compound of claim 1, or claim 2, wherein the compound is a compound of formula (I):or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:either(1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the Ci-ealkylene of L3 is optionally substituted with one or more Ci-ealkyl, and the 3-10 membered heterocyclyl is optionally substituted with one or more -OH;X1 and X2 are each independently N or C(R5); andR4 is:(i)     -S(O)2-Ra;(ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl;(iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH,(iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH,(v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-6 alkyl, or3-10 membered heterocycle, wherein the 3-10 membered heterocycle is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, NH-S(O)2-Ra, or -S(O)2-Ra,(vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl or oxo,(vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl),(viii) -CN; oror(2) L3 is absent; andone of X1 and X2 is N or C(R5); andthe other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, whereinthe 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of halo, oxo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(0)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, or -S(O)2-Ci.6alkyl, andthe C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, andthe 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(0)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-wcycloalkyl, and 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, andthe C3-iocycloalkyl of Rc is optionally substituted with one or more -OH;Ra is, independently at each occurrence:(i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-6alkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl, or(ii) C3-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, or(iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl;1071R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, wherein the Ci-ealkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-ealkoxy is optionally substituted with one or more halo; andR6 and R7 are each independently H or halo.

4. The compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L2 is -O-, such that the compound is a compound of formula (I-A):or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

5. The compound of any one of claims 1-4, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 1, or 2.

6. The compound of any one of claims 1-5, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R2 is H, Ci-3alkyl, C3-6cycloalkyl, or 3-10 membered heterocyclyl, wherein the Ci-3alkyl of R2 is optionally substituted with one or more deuterium, halo, -OH, -NH2, or Ci-3alkoxy, and the C3-6cycloalkyl of R2 is optionally substituted with one or more -OH.

7. The compound of any one of claims 1-6, or a stereoisomer or tautomer thereof, or apharmaceutically acceptable salt of any of the foregoing, wherein m is 0, 1, or 2.

8. The compound of any one of claims 1-7 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1 is halo, -CN, or -Ci-3alkyl, wherein the Ci-3alkyl of R1 is optionally substituted with one or more halo.

9. The compound of any one of claims 1-8, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein p is 0 or 1.

10. The compound of any one of claims 1-9, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R3 is Ci-ealkyl.

11. The compound of any one of claims 1-10, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L1 is Ci-3alkylene, wherein the Ci-3alkylene of L1 is optionally substituted with one or more deuterieum or Ci-3alkyl, wherein the Ci-3alkyl is optionally substituted with -OH or Ci-3alkoxy.

12. The compound of any one of claims 1-11, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L1 is selected from the groupeach L1, * denotes the point of attachment to L2 and ** denotes the point of attachment to the remainder of the molecule.

13. The compound of any one of claims 1-12, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L2 is O.

14. The compound of any one of claims 1-13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L3 is absent.

15. The compound of any one of claims 1-13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L3 is -O-, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, whereinthe C3-iocycloalkyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl,the Ci-ealkylene of L3 is optionally substituted with one or more -OH or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, andthe 3-10 membered heterocyclyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl.

16. The compound of any one of claims 1-13, and 15 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L3 is selected from the group17. The compound of any one of claims 1-16 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R4 is S(O)2-Ra, 5-10 membered heteroaryl, -N(Rd)2, -NS(O)-(Ci-3alkyl)2, -C(O)-N(Re)2, 3-6 membered heterocyclyl, -S(O)(N-Ci-3alkyl)-(Ci-3alkyl), -CN, -OH, -C(O)-Ci-3alkyl, or -P(O)(Ci-3alkyl)2, whereinthe 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-3alkyl, and the 3-6 membered heterocyclyl optionally substituted with one or more -OH, oxo, Ci-3alkyl, or -S(O)2-Ra18. The compound of claim 17 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Ra is Ci-ealkyl, C3-iocycloalkyl, or 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Ra is optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl,the C3-iocycloalkyl of Ra is optionally substituted with one or more -OH, C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-6alkyl)2, -C(0)-C3-ioheterocyclyl or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, andthe 3-10 membered heterocyclyl of Ra is optionally substituted with one or more Ci-ealkyl.

19. The compound of claim 17, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Rd is independently at each occurrence H, Ci-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH, and wherein Ra is Ci-ealkyl.

20. The compound of claim 17, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Re is independently at each occurrence H, Ci-ealkyl, or 3-10 membered heterocycle, wherein the 3-6 membered heterocycle is optionally substituted with one or more oxo.

21. The compound of claim 17 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, wherein the 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, -NH2, -NH-S(O)2-Ra, or -S(O)2-Ra, wherein Ra is Ci-ealkyl.

22. The compound of any one of claims 1-21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein each of X1 and X2 is C(R5).

23. The compound of any one of claims 1-21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein each of X1 and X2 is N.

24. The compound of any one of claims 1-21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of X1 and X2 is N and the other is C(R5).

25. The compound of any one of claims 1-21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of X1 and X2 is N or CR5, and the other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl optionally substituted with one or more of Rb.

26. The compound of claim 25, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Rb is independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-3alkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-3alkyl, or C3-ecycloalkyl, and wherein the C3-6cycloalkyl of the Ci-3alkyl of Rb is further optionally substituted with one or more Ci-3alkyl or -OH and the C3-6cycloalkyl of Rb is optionally substituted with one or more -OH, C3-6cycloalkyl, or Ci-3alkyl, and wherein the Ci-3alkyl of the C3-6cycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium, or halo.

27. The compound of any one of claims 1-21, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of X1 and X2 is N or CR5, and the other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heteroaryl optionally substituted with one or more Rc.

28. The compound of claim 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein, Rc is independently at each occurrence, selected from the group consisting of halo, Ci-3alkyl, -C(O)-Ci-3alkyl, -C(O)-NH2, -C(O)-NH(Ci-3alkyl), -C(O)-N(Ci-3alkyl)2, -S(O)2-Ra, C3-6cycloalkyl, and 3-6 membered heterocyclyl, wherein the Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-3alkyl, the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH, or Ci-3alkyl, and the 3-6 membered heterocyclyl of Rc 1076is optionally substituted with one or more -OH or Ci-3alkyl, and wherein the Ci-3alkyl of the 3-6 membered heterocyclyl of Rc is further optionally substituted with one or more -OH.

29. The compound of any one of claims 1-28, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R5 is independently at each occurrence, H, halo, -CN, 3-6 membered heterocyclyl, Ci-3alkyl, or Ci-3alkoxy, wherein the Ci-3alkyl of R5 is optionally substituted with one or more halo, or -OH and wherein the Ci-3alkoxy is optionally substituted with one or more halo.

30. The compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, is selected from Compounds 1-472 of Table 1.

31. A method for preparing a compound of formula (II), as recited in claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprises a step of reacting a compound of formula (IT-A):R2wherein:m is an integer from 0 to 4;n is an integer from 0 to 2;p is an integer from 0 to 10;R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-ealkoxy, and Ci-ealkyl, whereinthe Ci-ealkoxy of R1 is optionally substituted with one or more halo, andthe Ci-ealkyl of R1 is optionally substituted with one or more halo;R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, whereinthe Ci-ealkyl of R2 is optionally substituted with one or more deuterium, halo, -OH, -NH2, orCi-ealkoxy, andthe C3-iocycloalkyl of R2 is optionally substituted with one or more -OH;R3, if present, is Ci-ealkyl;with:a compound of formula (II’ -B):Y1y-x**k1= / L3r4 (ir-B),wherein:the dashed line represents a single or double bond;Y1 is halo, oxo, or a sulfonate esterL1 is Ci-ealkylene, whereinthe Ci-ealkylene of L1 is optionally substituted with one or more deuterium or Ci-ealkyl, and whereinthe Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy;L2 is O or N(RX), wherein Rx is H or Ci-ealkyl; andeither(1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl, the Ci-ealkylene of L3 is optionally substituted with one or more -OH or Ci-6alkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, andthe 3-10 membered heterocyclyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl;X1 and X2 are each independently N or C(R5); andR4 is:(i)     -S(0)2-Ra;(ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl;(iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH,(iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-6 alkyl, or 3-10membered heterocycle, whereinthe 3-10 membered heterocycle of Re is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, whereinthe 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra,(vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH , oxo or -S(O)2Ra,(vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl),(viii) -CN,(ix) -(CH2)?OH, wherein q is an integer from 0-6,(x) -C(O)-Ci-ealkyl, or(xi) -P(O)(Ci-6alkyl)2;or(2) L3 is absent; andone of X1 and X2 is N or C(R5); andthe other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, whereinthe 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein Rb is, independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, Cs-iocycloalkyl, and 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, and whereinthe C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH andthe C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, C3-iocycloalkyl, or Ci-ealkyl, and whereinthe Ci-ealkyl of the C3-iocycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium, or halo, andthe 5-20 membered heteroaryl is optionally substituted with one or more Rc, wherein Rc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(O)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-6alkyl, the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, andthe 3-10 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and whereinthe Ci-ealkyl of the 3-10 membered heterocyclyl of Rc is further optionally substituted with one or more -OH;Ra is, independently at each occurrence:(i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-6alkyl, or -N(Ci-6alkyl)-C(O)-Ci-ealkyl,(ii) C3-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-6alkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-6alkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, whereinthe Ci-ealkyl is optionally substituted with one or more -OH,(iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, or(iv) NH(Ci-ealkyl);R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, whereinthe Ci-ealkyl of R5 is optionally substituted with one or more halo or -OH, and1080the Ci-ealkoxy of R5 is optionally substituted with one or more halo;X3 is N or C(R6);X4 is N or C(R7);andR6 and R7 are each independently H or halo;to give a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

32. The method of claim 31, wherein the compound of claim 1 is prepared by a step comprising: a) alkylation of an amine of formula (IT-A) with an alkyl halide, or sulfonate estercompound of formula (IT -B) in the presence of an inorganic base; orb) reductive amination of a ketone of formula (II’-B) with an amine of formula (IT-A).

33. The method of claim 32, wherein the inorganic base is selected from the group consisting of potassium carbonate, and sodium bicarbonate.

34. The method of claim 32, wherein the reductive amination proceeds under the action of sodium triacetoxyborohydride, titanium tetraiopropoxide and acetic acid.

35. A method for preparing a compound of formula (II), as recited in claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprising a step of reacting a compound of formula (II’-C):R2\l 2(II’-C), wherein:m is an integer from 0 to 4;n is an integer from 0 to 2;p is an integer from 0 to 10;R1, if present is, independently at each occurrence selected from the group consisting of halo, -CN, Ci-ealkoxy, and Ci-ealkyl, whereinthe Ci-ealkoxy of R1 is optionally substituted with one or more halo, andthe Ci-ealkyl of R1 is optionally substituted with one or more halo;R2 is H, Ci-ealkyl, C3-iocycloalkyl, or 3-15 membered heterocyclyl, whereinthe Ci-ealkyl of R2 is optionally substituted with one or more deuterium, halo, -OH, -NH2, or Ci-ealkoxy, andthe C3-iocycloalkyl of R2 is optionally substituted with one or more -OH;R3, if present, is Ci-ealkyl;L1 is Ci-ealkylene, whereinthe Ci-ealkylene of L1 is optionally substituted with one or more deuterium or Ci-ealkyl, and whereinthe Ci-ealkyl is further optionally substituted with one or more -OH or Ci-ealkoxy; andY2 is halo, -OH or -NH2;with:a compound of formula (II’ -D):Y3^x4*3 'Vx1= / Y3R" (ir-D),wherein:Y3 is -OH or -NH(RX), wherein each Rx is independtly H or Ci-ealkyl; and either(1) L3 is absent or is O, C3-iocycloalkyl, 3-10 membered heterocyclyl, or Ci-ealkylene, wherein the C3-iocycloalkyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl, the Ci-ealkylene of L3 is optionally substituted with one or more -OH or Ci-ealkyl, wherein the Ci-ealkyl is optionally substituted with one or more -OH, andthe 3-10 membered heterocyclyl of L3 is optionally substituted with one or more -OH or Ci-ealkyl;X1 and X2 are each independently N or C(R5); andR4 is:(i)     -S(O)2-Ra;(ii) 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of R4 is optionally substituted with one or more Ci-ealkyl;(iii) -N(Rd)2, wherein Rd is independently at each occurrence H, Ci-6 alkyl, or -S(O)2-Ra, wherein the Ci-ealkyl of Rd is optionally substituted with one or more -OH,(iv) -NS(O)-(Ci-ealkyl)2, wherein the Ci-ealkyl is optionally substituted with one or more -OH, (v)    -C(O)-N(Re)2 wherein Re is independently at each occurrence H, Ci-6 alkyl, or 3-10membered heterocycle, whereinthe 3-10 membered heterocycle of Re is optionally substituted with one or more oxo, or both Re together with the N to which they are attached are taken together to form a 3-10 membered heterocyclyl, whereinthe 3-10 membered heterocyclyl is optionally substituted with one or more halo, oxo, -OH, NH2, -NH-S(O)2-Ra, or -S(O)2-Ra,(vi) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, -OH, oxo or -S(O)2Ra,(vii) -S(O)-N(Ci-6alkyl)-(Ci-6alkyl),(viii) -CN,(ix) -(CH2)?OH, wherein q is an integer from 0-6,(x) -C(O)-Ci-ealkyl, or(xi) -P(O)(Ci-6alkyl)2; or(2) L3 is absent; andone of X1 and X2 is N or C(R5); andthe other of X1 and X2 is N or C that is taken together with R4, and the atoms to which they are attached, to form a 5-10 membered heterocyclyl or a 5-20 membered heteroaryl, whereinthe 5-10 membered heterocyclyl is optionally substituted with one or more Rb, wherein1083Rb is, independently at each occurrence, selected from the group consisting of -OH, halo, oxo, Ci-6alkyl, -C(O)-Ci-6alkyl, -C(0)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-ealkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, wherein the Ci-ealkyl of Rb is optionally substituted with one or more halo, OH, -S(O)2-Ci-ealkyl, or C3-iocycloalkyl, and whereinthe C3-iocycloalkyl of the Ci-ealkyl of Rb is further optionally substituted with one or more Ci-ealkyl or -OH andthe C3-iocycloalkyl of Rb is optionally substituted with one or more -OH, C3-iocycloalkyl, or Ci-ealkyl, and whereinthe Ci-ealkyl of the C3-iocycloalkyl of Rb is further optionally substituted with one or more -OH, deuterium, or halo, and the 5-20 membered heteroaryl is optionally substituted with one or more Rc, whereinRc is, independently at each occurrence, selected from the group consisting of halo, Ci-ealkyl, -C(O)-Ci-6alkyl, -C(0)-NH2, -C(O)-NH(Ci-6alkyl), -C(O)-N(Ci-6alkyl)2, -S(O)2-Ra, C3-iocycloalkyl, and 3-10 membered heterocyclyl, whereinthe Ci-ealkyl of Rc is optionally substituted with one or more -S(O)2-Ci-ealkyl, the C3-iocycloalkyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, andthe 3-10 membered heterocyclyl of Rc is optionally substituted with one or more -OH or Ci-ealkyl, and whereinthe Ci-ealkyl of the 3-10 membered heterocyclyl of Rc is further optionally substituted with one or more -OH;Ra is, independently at each occurrence:(i) Ci-ealkyl optionally substituted with one or more halo, -OH, -S(O)2-Ci-ealkyl, or -N(Ci-6alkyl)-C(O)-Ci-6alkyl,(ii) C3-iocycloalkyl optionally substituted with one or more -OH, -C(O)2-Ci-ealkyl, -C(O)-NH(Ci-ealkyl), -C(O)-N(Ci-ealkyl)2, or -C(0)-C3-ioheterocyclyl, or Ci-ealkyl, whereinthe Ci-ealkyl is optionally substituted with one or more -OH,(iii) 3-10 membered heterocyclyl optionally substituted with one or more Ci-ealkyl, or(iv) NH(Ci-ealkyl);R5 is, independently at each occurrence, H, halo, -CN, 3-10 membered heterocyclyl, Ci-ealkyl, or Ci-ealkoxy, whereinthe Ci-ealkyl of R5 is optionally substituted with one or more halo or -OH, andthe Ci-ealkoxy of R5 is optionally substituted with one or more halo;X3 is N or C(R6);X4 is N or C(R7);andR6 and R7 are each independently H or halo;to give a compound of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

36. The method of claim 35, wherein the compound of claim 1 is prepared by a step comprising: a) coupling of an alcohol compound of formula (II’-C) with a phenol compound of formula(II’-D), or a heterocyclic variant, under Mitsunobu-type reaction conditions; orb) reacting an alkyl halide compound of formula (II’-C) with a phenol or amine compound of formula (II’-D), in the presence of a catalyst.

37. The method of claim 36, wherein the Mitsunobi-type reaction conditions comprises coupling of an alcohol compound of formula (II’-C) with a phenol compound of formula (II’-D), or a heterocyclic variant, in the presence of triphenylphosphine and diisopropyl azodi carb oxy late.

38. The method of claim 37, wherein the catalyst is silver oxide or potassium carbonate.

39. A pharmaceutical composition, comprising (i) a compound of any one of claims 1-30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

40. A method of modulating APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of any one or claims 1-30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical 1085composition of claim 39.

41. A method of inhibiting APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of any one or claims 1-30 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 39.

42. A method of treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual a compound of any one of claims 1-30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 39.

43. The method of claim 42, wherein the disease, disorder, or condition is selected from the group consisting of chronic kidney disease, focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN), sickle-cell nephropathy, lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, viral nephropathy, COVID-19 associated nephropathy, preeclampsia, and sepsis.

44. The method of claim 42 or claim 43, wherein the disease, disorder, or condition is a kidney disease.

45. The method of any one of claims 40-44, wherein the disease, disorder, or condition is a chronic kidney disease (CKD).

46. A method of delaying the development of an APOL1-mediated disease, disorder, or condition, comprising administering a compound of any one of claims 1-30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 39, to an individual who is at risk of developing an APOL1-mediated disease, disorder, or condition.

47. The method of claim 46, wherein the APOL1-mediated disease, disorder, or condition is a kidney disease.

48. The method of claim 46 or claim 47, wherein the APOL1-mediated disease, disorder, or condition is a chronic kidney disease.

49. The method of claim 46, wherein the APOL1-mediated disease, disorder, or condition is selected from the group consisting of chronic kidney disease, focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN), sickle-cell nephropathy, lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, viral nephropathy, COVID-19 associated nephropathy, preeclampsia, and sepsis.

50. The method of any one of claims 40-49, wherein the individual has an APOL1 mutation.

51. The method of claim 50, wherein the APOL1 mutation is a gain-of-function mutation.

52. The method of any one of claims 42-51, wherein a therapeutically effective amount of acompound of any one of claims 1-30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 39, is administered.

53. A kit, comprising (i) a compound of any one of claims 1-30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 39, and (ii) instructions for use in treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof.

54. The kit of claim 53, wherein the disease, disorder, or condition is a kidney disease.

55. The kit of claim 53 or claim 54, wherein the disease, disorder, or condition is a chronic kidney disease (CKD).

56. The kit of any one of claims 53-55, wherein the disease, disorder, or condition is selected from the group consisting of chronic kidney disease, focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN), sickle-cell nephropathy, lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, viral nephropathy, COVID-19 associated nephropathy, preeclampsia, and sepsis.

57. The kit of any one of claims 53-56, wherein the individual has an APOL1 mutation.

58. The kit of claim 57, wherein the APOL1 mutation is a gain-of-function mutation.